Methods of preparing and using quinazoline and quinoline derivatives

ABSTRACT

A method of preparing a compound of formula (I), 
     
       
         
         
             
             
         
       
     
     A method for treating cancer or inhibiting growth of cancer cells including administering to a patient mammal in need thereof a pharmaceutical preparation including the compound. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal including administering to a mammal a pharmaceutical preparation including the compound.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No. 12/787,548, filed on May 26, 2010, now pending, which is a continuation-in-part of U.S. application Ser. No. 12/342,104, filed on Dec. 23, 2008, issued as U.S. Pat. No. 7,754,729, on Jul. 13, 2010, which is a continuation of Int'l Pat. Appl. No. PCT/CN2007/001920 filed on Jun. 19, 2007. This Application also claims foreign priority benefits to Chinese Pat. Appl. Nos. 200610014690.1 filed on Jul. 5, 2006 and 200610138377.9 filed on Nov. 10, 2006. The contents of all of the aforementioned Applications, including any intervening amendments thereto, are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to a method of preparation of quinazoline and quinoline derivatives, and a method of using the same as pharmaceutical agents.

2. Description of the Related Art

Protein tyrosine kinases (PTKs) modulate a wide variety of cellular events, including differentiation, growth, metabolism, and apoptosis. Transmembrane receptor tyrosine kinases (RTKs), members of the PTK family, are the high affinity cell surface receptors for many polypeptide growth factors, cytokines and hormones.

The mechanisms by which most RTKs transmit signals are now well established. Binding of ligand results in the dimerization of receptor monomers followed by transphosphorylation of tyrosine residues within the cytoplasmic domains of the receptors. However, mutations in the transmembrane (TM) domains of RTKs have been implicated in the induction of pathological phenotypes. These mutations are believed to stabilize the RTK dimers, and thus promote unregulated signaling without ligand binding.

Overexpression of PTK in cells can cause weak signals to be amplified. Furthermore, during many steps of cellular signal transfer, the occurrence of mutations or overexpression of PTK can cause false signals. These false signals play a role in carcinogenesis.

Epidermal growth factor receptor (EGFR) is one of the typical examples. EGFR belongs to cell surface receptors of epidermal growth factor receptor tyrosine kinase (EGFR-TK). The receptor family comprises EGF receptor (a protein product of oncogene erbB-1), erbB-2 (c-neu or HER2) receptor, tumor protein mutant erbB-3 receptor, and erbB-4 receptor. EGF and transforming growth factor alpha (TGFα) are the two most important ligands of EGFR. Though the receptor plays a minor role in healthy adults, it is closely related to the pathological process of most cancers, particularly to colon cancer and breast cancer. Therefore, an EGFR-TK inhibitor that can block the transfer of these receptor signals can be used to treat cancers caused by EGFR overexpression, such as colorectal cancer, breast cancer, kidney cancer, lung cancer, and head and neck cancer.

An EGFR-TK inhibitor can also be used to treat other diseases caused by EGFR overexpression, such as psoriasis, nephritis and pancreatitis which are described below.

Conventional treatments for proliferative skin diseases such as psoriasis include anti-cancer drugs, such as methotrexate. However, methotrexate has strong side effects and response is poor within the necessary limited dosage. In psoriatic tissues, TGFα is the main growth factor that is overexpressed. In animal experiments, 50% of transgenic mice with TGFα overexpression produce psoriasis, which suggests that a good inhibitor of EGFR signal transfer mechanism may inhibit psoriasis, i.e., the EGFR-TK inhibitor can relieve psoriasis symptoms.

EGF is an important epithelial mitogen and plays a role in renal tubular cell replication. In streptozotocin-induced diabetic mice, secretion of urine and mRNA of EGF are increased fourfold. Additionally, the expression of EGFR is enhanced in patients with proliferative glomerulonephritis (Roy-Chaudhury et al., Pathology, 1993, 25, 327-332). These findings indicate blocking EGF singal transfer can be used to treat and prevent renal injury. Therefore, it is postulated that an EGFR-TK inhibitor could be used to treat proliferative glomerulonephritis and renal disease induced by diabetes.

It has been reported that in chronic pancreatitis patients the expression of EGFR and TGFα is much higher than in healthy adults (Korc et al., Gut, 1994, 35, 1468). The overexpression of erbB-2 receptor has been confirmed in patients with severe chronic pancreatitis (Friess et al., Ann. Surg., 1994, 220, 183). Therefore, it is postulated that an EGFR-TK inhibitor could potentially be used to treat pancreatitis.

During embryonic cell maturation, embryonic cell implantation in endometrium, and other peripheral implantation, EGF and TGFα are present in uterine tissues (Taga, Nippon Sanka Fujinka Gakkai Zasshi, 1992, 44, 939) and EGFR levels are increased (Brown et al., Endocrinology, 1989, 124, 2882). Meanwhile, heparin-binding EGF (HB-EGF) is expressed in the uterus in a blastocyst-mediated process. (Das et al, Development, 1994, 120, 1071). TGFα and EGFR are highly expressed in embryonic cells (Adamson, Mol. Reprod. Dev., 1990, 27, 16). Surgical removal the submandibular gland and treatment with monoclonal antibody against EGFR can greatly reduce the fertility of mice by decreasing the success of embryonic cell implantation (Tsutsumi et al., J. Endocrinology, 1993, 138, 437). These results indicate that an EGFR-TK inhibitor may function as a contraceptive.

WO1992/007844 and WO1992/014716 disclose 2,4-diaminoquinazoline derivatives which are used as potentiators of chemotherapeutic agents in the treatment of cancer.

WO1992/020642 discloses bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase.

EP520722, EP566226, EP635498, EP602851, WO 1995/019774 and WO 1995/15758 relate to reversible EGF receptor tyrosine kinase inhibitors. These inhibitors belong to the family of aryl and heteroaryl quinazoline derivatives and some exhibit a high inhibitory activity against EGF receptor tyrosine kinase. However, in animal pathological models these inhibitors exhibit low activity. The reason for this lies in that PTK is a catalyst catalyzing a phosphate group to transfer from ATP to a protein tyrosine residue, and the above-mentioned reversible EGF receptor tyrosine kinase inhibitors compete with ATP to bind EGF receptor tyrosine kinase, but in cells the ATP concentration is much higher (mM grade). Thus, the reversible EGF receptor tyrosine kinase inhibitors exhibiting a high activity in vitro have difficulty functioning in pathological animal models. However, since irreversible EGF receptor tyrosine kinase inhibitors do not compete with ATP, they are expected to do better in vivo.

Irreversible EGF receptor tyrosine kinase inhibitors are known and much effort has been devoted to their development. One type of irreversible EGF receptor tyrosine kinase inhibitors features a Michael acceptor at the sixth position of quinazoline, so that a Michael addition reaction can occur between the inhibitor and cysteine sulfhydryl in the active center pocket wall of EGF receptor tyrosine kinase. Furthermore, the activity of the inhibitor has a positive correlation with the activation energy of the Michael addition reaction between the inhibitor and cysteine sulfhydryl.

SUMMARY OF THE INVENTION

In view of the above-described problems, it is an objective of the invention to provide a compound or pharmaceutically acceptable salt or hydrate thereof which can inhibit protein tyrosine kinase activity.

It is another objective of the invention to provide a pharmaceutical preparation comprising an excipient and a compound or pharmaceutically acceptable salt or hydrate thereof which inhibits protein tyrosine kinase activity.

It is still another objective of the invention to provide a method of preparing a compound which irreversibly inhibits protein tyrosine kinase activity.

To achieve the above objectives, in accordance with one embodiment of the invention, provided is a compound of formula (I),

wherein X represents N, C—CN, or CH; Y represents CH₂, S, O or N—R⁹; R¹, R³, R⁷ and R⁸ independently represent H, CF₃, or C₁₋₆alkyl; R² represents a group selected from formula (II), (III), (IV), (V), (VI), (VII) or (VIII);

R⁴ and R⁶ independently represent H, C₁₋₆alkyl, OC₁₋₆alkyl, OH, F, Cl, Br, OCF₃, or trifluoromethyl; R⁵ is independently at each occurrence selected from H, F, C₁₋₆alkyl, OH, OC₁₋₆ alkyl, OCF₃, OCF₂CH₃, NH₂, NH(C₁₋₆alkyl), N(C₁₋₆alkyl)₂, 1-pyrrolinyl, 1-piperidyl, 4-morpholinyl, Cl, Br, trifluoromethyl, O(CH₂)₂₋₄OCF₃, O(CH₂)₂₋₄OC₁₋₆alkyl, O(CH₂)₂₋₄NH(C₁₋₆alkyl), O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄O, (1-piperidyl)(CH₂)₂₋₄O, (4-morpholinyl)(CH₂)₂₋₄O, NHC(O)H, NHC(O)(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)(C₁₋₆alkyl), O(CH₂)₂₋₄OH, N(C₁₋₆alkyl)C(O)O(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)OH, NHC(O)O(C₁₋₆alkyl), OC(O)NH(C₁₋₆alkyl), OC(O)N(C₁₋₆alkyl)₂, (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-imidazolyl)(CH₂)₂₋₄O, (4-imidazolyl)(CH₂)₂₋₄OC(O), (pyrazolyl)(CH₂)₂₋₄O, (triazolyl)(CH₂)₂₋₄OC(O) or Ar(CH₂)₁₋₄O; R⁹ at each occurrence is independently selected from H, C₁₋₆alkyl, CF₃, CF₂CH₃, (CH₂)₂₋₄OH, (CH₂)₁₋₄OC₁₋₆alkyl, (CH₂)₁₋₄NH(C₁₋₆alkyl), (CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₄, (1-piperidyl)(CH₂)₁₋₄, (4-morpholinyl)(CH₂)₁₋₄, C(O)C₁₋₆alkyl, C(O)(CH₂)₁₋₄OH, C(O)(CH₂)₁₋₄OC₁₋₆alkyl, C(O)(CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₆C(O), (1-piperidyl)(CH₂)₁₋₆C(O), (4-morpholinyl)(CH₂)₁₋₄C(O), C(O)OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄ N(C₁₋₆alkyl)₂, C(O)O(CH₂)₂₋₄NH(C₁₋₆alkyl), (1-pyrrolinyl) (CH₂)₂₋₄OC(O), (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (CH₂)₁₋₄C(O)OC₁₋₆alkyl, or Ar(CH₂)₁₋₄; R¹⁰ represents H, C₁₋₆alkyl, or F; R¹¹ and R¹² represent independently at each occurrence H, F, Cl, Br, I, CN, NO₂, CF₃, OH, NH₂, C₁₋₄alkyl, OC₁₋₄alkyl, OCF₃, OCF₂CH₃, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, OC(O)C₁₋₄alkyl, NHC(O)H, NHC(O)C₁₋₄alkyl, N(C₁₋₄alkyl)C(O)C₁₋₄alkyl, C(O)OC₁₋₄alkyl, C(O)NHC₁₋₄alkyl, C(O)N(C₁₋₄alkyl)₂, COOH, C(O)C₁₋₄alkyl, S(O)C₁₋₄alkyl, SO₂C₁₋₄alkyl, SO₂NHC₁₋₄alkyl or SO₂N(C₁₋₄alkyl)₂; A, B independently represent aromatic ring; Ar is phenyl, substituted phenyl, or pyridyl; D represents O, S, NH, or methylene; m, n independently represent an integer from 0 to 4; z is 0, 1, or 2; and t and u independently represent an integer from 0 to 4.

As used herein the term “substituted phenyl” means phenyl substituted by one or more substituents selected from phenyl substituted by one or more halo, C₁₋₈alkyl, C₁₋₈alkoxy, carboxyl, C₁₋₈haloalkyl, C₁₋₈alkylthio, phenyl, nitro, amino, C₁₋₈alkylcarboxylamino, hydroxyl, acetyl, acetyloxy, phenoxy; C₁₋₈alkoxycarbonyl, or C₁₋₈alkylcarbonyl.

In the embodiments of the invention, C₁₋₄alkyl and C₁₋₆alkyl are straight chain alkyl, branched chain alkyl, or cyclic alkyl, saturated or unsaturated alkyl, optionally substituted with F, OH, COOH, CO₂(C₁₋₄alkyl), C(O)NH₂, C(O)NH(C₁₋₄alkyl), C(O)N(C₁₋₄alkyl)₂, NHC(O)(C₁₋₄alkyl), NH₂, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, NHC(O)NH₂, NHC(NH)NH₂, O(C₁₋₄alkyl), or S(C₁₋₄alkyl).

When A, B independently represent an aromatic ring, the ring is a 5 to 7-membered and contains from 0 to 4 heteroatoms, such as N, O or S. A, B can also independently represent a polycyclic aromatic group consisting of two or three 5 to 7-membered fused rings.

In the embodiments of the invention, the connecting position of the group R² connected to the amine group of the fourth position of the mother nucleus is not limited to the position as shown by the broken line, other position is also applicable.

When the compound of formula (I) is defined as an E/Z isomer, it can be an E isomer or a Z isomer or a mixture of an E isomer and a Z isomer.

When the compound of formula (I) is defined as an R/S isomer, it can be an R isomer, or an S isomer, or a mixture of an R isomer and an S isomer.

The uniqueness of the compound of the invention is clearly visualized by comparing the structure and property of the compound of Example 33 with the comparison compound A of Example 84, compound B of Example 85 and compound C.

The comparison compound C is an irreversible small molecular EGFR-TK inhibitor having the highest activity among all literature-reported compounds. At a molecular level, the EC₅₀ value of the comparison compound C against EGFR-TK is 10⁻⁷ μM, while in the same test EC₅₀ value of the comparison compound B is merely about 0.5 μM, which means the activity of the comparison compound B is five million times lower compared to the comparison compound C. The difference between the two compounds in chemical structure is merely the difference in the steric hindrance of substituted branch of the sixth position. Based on that rule, the activity of the compound of the invention should be lower than that of the comparison compound B.

However, in a test of inhibitory activity of EGFR-TK at cellular level, the activity of the compound of the invention was unexpectedly several orders of magnitude higher than that of the comparison compound B. For example, the activity of the compound in Example 33 is not only much higher than that of the comparison compound B, but also close to the comparison compound A (as shown in Table 3, 4). However, the EC₅₀ value of the comparison compound A and C against EGFR-TK is equivalent at the molecular level, which means that the activity of the compound in Example 33 is equivalent to that of the comparison compound C, and it is a million times higher than that of the comparison compound B.

It has been reported in the literature that the activity of an irreversible EGFR-TK inhibitor is ten times higher than that of a reversible EGFR-TK inhibitor in A431 animal tumor model, but that the activity of the two is equivalent at a molecular level. The compound of the present invention is proven to be an irreversible EGFR-TK inhibitor by a cellular model test (as shown in Table 5), while the high activity comparison compound A to be a reversible inhibitor in the same test, which conforms to the results of a direct test using EGFR-TK described in the literature.

The compounds of the invention also inhibit Her-2 TK, and part of the results are listed in Table 6.

The compounds of the invention show a certain degree of growth inhibition against epidermal cancer cell strain A431, colorectal cancer cell strain LoVo, breast cancer cell strain BT 474 and breast cancer cell strain SK-Br-3. A part of the test results are listed in Tables 7, 8 and 9. Some compounds have 30 times higher growth-inhibition activities against A431 than Tarceva (as shown in Table 7). Some compounds have equivalent growth-inhibition activities against breast cancer with Lapatinib (as shown in Table 8). Some have better growth-inhibition activities against colorectal cancer cell LoVo than adriamycin (as shown in Table 9).

Accordingly, the invention teaches a method of inhibiting cancer cell growth in mammals comprising administering to a mammal in need thereof the compound of formula (I) or pharmaceutically acceptable salt or hydrate thereof, wherein the cancer includes but is not limited to breast cancer, skin cancer, colorectal cancer, head and neck cancer, lung cancer, kidney cancer, bladder cancer, ovarian cancer, oral cancer, laryngeal cancer, esophageal cancer, gastric cancer, cervical cancer, or liver cancer.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R¹ represents H, CH₃, or CH₂CH₃, more particularly R¹ represents H.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R³ represents H, CH₃ or CH₂CH₃, more particularly R³ represents H.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R⁷ represents H, CH₃ or CH₂CH₃, more particularly R⁷ represents H.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R⁸ represents H, CH₃ or CH₂CH₃, more suitably R⁸ represents H.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R⁴ represents H, F, CH₃, CH₂CH₃, CH₂CH₂CH₃, OCH₃, or OCH₂CH₃; more particularly, R⁴ represents H, F, CH₃, CH₂CH₃ or OCH₃; and most particularly, R⁴ represents H, F, CH₃, or OCH₃.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R⁶ represents H, F, CH₃, CH₂CH₃, CH₂CH₂CH₃, OCH₃, OCF₃ or OCH₂CH₃; more particularly, R⁶ represents H, F, CH₃, CH₂CH₃ or OCH₃; and most particularly, R⁶ represents H, F, CH₃, or OCH₃.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein A represents benzene ring, pyridine, pyrimidine, pyrazine, 4-nitrogen heterocyclic pyridine, pyrrole, furan, thiophene, pyrazole, thiazole, indole, benzofuran, benzothiophene, or naphthalene ring; more particularly, A represents benzene ring, pyridine, thiophene, pyrazole, thiazole, indole, or naphthalene ring.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein B represents benzene ring, pyridine, pyrimidine, pyrazine, 4-nitrogen heterocyclic pyridine, pyrrole, furan, thiophene, pyrazole, thiazole, indole, benzofuran, benzothiophene or naphthalene ring; and more particularly, B represents benzene ring, pyridine, thiophene, pyrazole, thiazole, indole, or naphthalene ring.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein D represents O, S, or NH; more particularly, D represents O.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R¹⁰ represents H, F, CH₃, CF₃, or Et, and z is 0, 1, or 2; more particularly, R¹⁰ represents H, F, CH₃, or CF₃, and z is 0, 1 or 2; and most particularly, z is 0.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R¹¹ represents independently at each occurrence H, F, Cl, Br, CN, NO₂, CF₃, OH, CH₃, CH₂CH₃, CH₂CH₂CH₃, alkynyl, OCH₃, OCH₂CH₃, OCF₃, CO₂CH₃, CO₂CH₂CH₃, NH₂, NHCH₃, NHCH₂CH₃, N(CH₃)₂, NHC(O)H, NHC(O)CH₃, NHC(O)CH₂CH₃, N(CH₃)C(O)CH₃, C(O)NHCH₃, C(O)NHCH₂CH₃ or C(O)N(CH₃)₂; more particularly, R¹¹ represents independently at each occurrence H, F, Cl, Br, CN, CF₃, OH, CH₃, CH₂CH₃, ethynyl, OCH₃, OCH₂CH₃, OCF₃, CO₂CH₃, CO₂CH₂CH₃, NH₂, NHCH₃, NHCH₂CH₃, N(CH₃)₂ or NHC(O)CH₃, most particularly, R¹¹ represents independently at each occurrence H, F, Cl, Br, CN, CF₃, CH₃, CH₂CH₃, ethynyl, OCH₃, OCH₂CH₃, OCF₃, CO₂CH₂CH₃, NH₂, NHCH₃, NHCH₂CH₃, N(CH₃)₂, or NHC(O)CH₃.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein t is an integer from 1 to 4; and more particularly t is 1 or 2.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R¹² represent independently at each occurrence H, F, Cl, Br, CN, NO₂, CF₃, OH, CH₃, CH₂CH₃, CH₂CH₂CH₃, alkynyl, OCH₃, OCH₂CH₃, OCF₃, CO₂CH₃, CO₂CH₂CH₃, NH₂, NHCH₃, NHCH₂CH₃, N(CH₃)₂, NHC(O)H, NHC(O)CH₃, NHC(O)CH₂CH₃, N(CH₃)C(O)CH₃, C(O)NHCH₃, C(O)NHCH₂CH₃ or C(O)N(CH₃)₂; and more particularly, R¹² represent independently at each occurrence H, F, Cl, Br, CN, CF₃, OH, CH₃, CH₂CH₃, ethynyl, OCH₃, OCH₂CH₃, OCF₃, CO₂CH₃, CO₂CH₂CH₃, NH₂, NHCH₃, NHCH₂CH₃, N(CH₃)₂, or NHC(O)CH₃.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein u is an integer from 1 to 4; and more particularly u is 1 or 2.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R⁵ is independently at each occurrence selected from H, F, OH, CH₃, CH₂CH₃, CH₂CH₂CH₃, OCH₃, OCH₂CH₃, OCF₃, OCF₂CH₃, NH₂, NHCH₃, N(CH₃)₂, 1-pyrrolinyl, 1-piperidyl, 4-morpholinyl, trifluoromethyl, O(CH₂)₂OH, O(CH₂)₃OH, O(CH₂)₄OH, O(CH₂)₂OCH₃, O(CH₂)₃OCH₃, O(CH₂)₄OCH₃, O(CH₂)₂OCH₂CH₃, O(CH₂)₃OCH₂CH₃, O(CH₂)₄OCH₂CH₃, O(CH₂)₂N(CH₃)₂, O(CH₂)₃N(CH₃)₂, O(CH₂)₄N(CH₃)₂, O(CH₂)₂N(CH₂CH₃)₂, O(CH₂)₃N(CH₂CH₃)₂, O(CH₂)₄N(CH₂CH₃)₂, O(CH₂)₂N(CH₃)CH₂CH₃, O(CH₂)₃N(CH₃)CH₂CH₃, O(CH₂)₄N(CH₃)CH₂CH₃, O(CH₂)₂NH(CH₃), O(CH₂)₃NH(CH₃), O(CH₂)₄NH(CH₃), (1-pyrrolinyl)(CH₂)₂O, (1-pyrrolinyl)(CH₂)₃O, (1-pyrrolinyl)(CH₂)₄O, (1-piperidyl)(CH₂)₂O, (1-piperidyl) (CH₂)₃O, (1-piperidyl)(CH₂)₄O, (4-morpholinyl)(CH₂)₂O, (4-morpholinyl)(CH₂)₃O, (4-morpholinyl)(CH₂)₄O, NHC(O)H, NHC(O)CH₃, NHC(O)CH₂CH₃, NHC(O)CH₂CH₂CH₃, N(CH₃)C(O)H, N(CH₃)C(O)CH₃, N(CH₃)C(O)CH₂CH₃, N(CH₃)C(O)CH₂CH₂CH₃, NHC(O)OCH₃, NHC(O)OCH₂CH₃, N(CH₃)C(O)OCH₃, N(CH₃)C(O)OCH₂CH₃, N(CH₃)C(O)OCH₂CH₂CH₃, OC(O)NHCH₃, OC(O)NHCH₂CH₃, OC(O)N(CH₃)₂, or OC(O)N(CH₃)CH₂CH₃.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein R⁹ is independently at each occurrence selected from H, CH₃, CH₂CH₃, CH₂CH₂CH₃, CF₃, CF₂CH₃, (CH₂)₂OH, (CH₂)₃OH, (CH₂)₄OH, (CH₂)₂OCH₃, (CH₂)₃OCH₃, (CH₂)₄OCH₃, (CH₂)₂OCH₂CH₃, (CH₂)₃OCH₂CH₃, (CH₂)₄OCH₂CH₃, (CH₂)₂N(CH₃)₂, (CH₂)₃N(CH₃)₂, (CH₂)₄N(CH₃)₂, (CH₂)₂N(CH₂CH₃)₂, (CH₂)₃N(CH₂CH₃)₂, (CH₂)₄N(CH₂CH₃)₂, (CH₂)₂N(CH₃)CH₂CH₃, (CH₂)₃N(CH₃)CH₂CH₃, (CH₂)₄N(CH₃)CH₂CH₃, (CH₂)₂NH(CH₃), (CH₂)₃NH(CH₃), (CH₂)₄NH(CH₃), (1-pyrrolinyl)(CH₂)₂—, (1-pyrrolinyl)(CH₂)₃—, (1-pyrrolinyl)(CH₂)₄—, (1-piperidyl)(CH₂)₂—, (1-piperidyl)(CH₂)₃, (1-piperidyl)(CH₂)₄, (4-morpholinyl)(CH₂)₂, (4-morpholinyl)(CH₂)₃, (4-morpholinyl)(CH₂)₄, C(O)CH₃, C(O)CH₂CH₃, C(O)CH₂CH₂CH₃, C(O)(CH₂)₄OH, C(O)CH₂OH, C(O)(CH₂)₂OH, C(O)(CH₂)₃OH, C(O)CH₂OCH₃, C(O)(CH₂)₂OCH₃, C(O)(CH₂)₃OCH₃, C(O)(CH₂)₄OCH₃, C(O)CH₂OCH₂CH₃, C(O)CH₂N(CH₃)₂, C(O)(CH₂)₂N(CH₃)₂, C(O)(CH₂)₃N(CH₃)₂, C(O)(CH₂)₄N(CH₃)₂, C(O)CH₂N(CH₃)CH₂CH₃, C(O)(CH₂)₂N(CH₃)CH₂CH₃, C(O)(CH₂)₃N(CH₃)CH₂CH₃, C(O)(CH₂)₄N(CH₃)CH₂CH₃, C(O)CH₂NHCH₂CH₃, C(O)(CH₂)₂NHCH₂CH₃, C(O)(CH₂)₃NHCH₂CH₃, C(O)(CH₂)₄NHCH₂CH₃, C(O)CH₂NHCH₃, C(O)(CH₂)₂NHCH₃, C(O)(CH₂)₃NHCH₃, C(O)(CH₂)₄NHCH₃, C(O)CH₂NHPr, C(O)(CH₂)₂NHPr, C(O)(CH₂)₃NHPr, C(O)(CH₂)₄NHPr, C(O)CH₂N(CH₂CH₃)₂, C(O)(CH₂)₂N(CH₂CH₃)₂, C(O)(CH₂)₃N(CH₂CH₃)₂, C(O)(CH₂)₄N(CH₂CH₃)₂, (1-pyrrolinyl)CH₂C(O), (1-pyrrolinyl)(CH₂)₂C(O), (1-pyrrolinyl)(CH₂)₃C(O), (1-pyrrolinyl)(CH₂)₄C(O), (1-piperidyl)CH₂C(O), (1-piperidyl)(CH₂)₂C(O), (1-piperidyl)(CH₂)₃C(O), (1-piperidyl)(CH₂)₄C(O), (4-morpholinyl)(CH₂)₄C(O), (4-morpholinyl)(CH₂)₃C(O), (4-morpholinyl)CH₂C(O), (4-morpholinyl)(CH₂)₂C(O), C(O)OCH₃, C(O)OCH₂CH₃, C(O)OPr, C(O)OPr-i, C(O)O(CH₂)₂OCH₃, C(O)O(CH₂)₃OCH₃, C(O)O(CH₂)₄OCH₃, C(O)O(CH₂)₂OCH₂CH₃, C(O)O(CH₂)₂N(CH₃)₂, C(O)O(CH₂)₃N(CH₃)₂, C(O)O(CH₂)₄N(CH₃)₂, (1-pyrrolinyl)(CH₂)₂OC(O), (1-pyrrolinyl)(CH₂)₃OC(O), (1-pyrrolinyl)(CH₂)₄OC(O), (1-piperidyl)(CH₂)₂OC(O), (1-piperidyl)(CH₂)₃OC(O), (1-piperidyl)(CH₂)₄OC(O), (4-morpholinyl)(CH₂)₂OC(O), (4-morpholinyl)(CH₂)₃OC(O), (4-morpholinyl)(CH₂)₄OC(O), CH₂C(O)OCH₃, (CH₂)₂C(O)OCH₃, (CH₂)₃C(O)OCH₃, CH₂C(O)OCH₂CH₃, (CH₂)₂C(O)OCH₂CH₃, or (CH₂)₃C(O)OCH₂CH₃.

The compound of formula (I) suitable for being used as medical active ingredient comprises the compounds wherein m and n each independently represent an integer from 0 to 4; and particularly 0, 1 or 2.

TABLE 1 Examples of R⁹ and R¹¹ in the compound of formula (I) suitable for being used as active medical ingredient R⁹ R¹¹ R⁹ R¹¹ H H H 3-Cl H 3-Br H 3-F H 3-CH₃ H 3-CF₃ H 3-alkynyl H 3-CN H 3-NO₂ H 3-OCH₃ H 3-C(O)CH₃ H 3-SO₂CH₃ H 3-S(O)CH₃ H 3-CO₂CH₃ H 3-SO₂NHCH₃ H 3-CO₂CH₂CH₃ H 3-SO₂N(CH₃)₂ H 3-CONHCH₃ H 3-CON(CH₃)₂ H 4-CON(CH₃)₂ H 3-I H 4-Cl H 4-Br H 4-F H 4-CH₃ H 4-CF₃ H 4-alkynyl H 4-CN H 4-NO₂ H 4-OCH₃ H 4-C(O)CH₃ H 4-SO₂CH₃ H 4-S(O)CH₃ H 4-CO₂CH₃ H 4-SO₂NHCH₃ H 4-CO₂CH₂CH₃ H 4-SO₂N(CH₃)₂ H 4-CONHCH₃ H 4-F-3-Br H 4-F-3-I H 4-F-3-CH₃ H 4-F-3-CF₃ H 4-F-3-alkynyl H 4-F-3-CN H 4-F-3-NO₂ H 4-F-3-OCH₃ H 4-F-3-C(O)CH₃ H 4-F-3-SO₂CH₃ H 4-F-3-S(O)CH₃ H 4-F-3-CO₂CH₃ H 4-F-3-SO₂NHCH₃ H 4-F-3-CO₂CH₂CH₃ H 4-F-3-SO₂N(CH₃)₂ H 4-F-3-CONHCH₃ H 4-F-3-CON(CH₃)₂ H 3-F-4-F H 4-F-3-Cl CH₃ H CH₃ 3-Cl CH₃ 3-Br CH₃ 3-F CH₃ 3-CH3 CH₃ 3-CF₃ CH₃ 3-alkynyl CH₃ 3-CN CH₃ 3-NO2 CH₃ 3-OCH₃ CH₃ 3-C(O)CH₃ CH₃ 3-SO₂CH₃ CH₃ 3-S(O)CH₃ CH₃ 3-CO₂CH₃ CH₃ 3-SO₂NHCH₃ CH₃ 3-CO₂CH₂CH₃ CH₃ 3-SO₂N(CH₃)₂ CH₃ 3-CONHCH₃ CH₃ 3-CON(CH₃)₂ CH₃ 4-CON(CH₃)₂ CH₃ 3-I CH₃ 4-Cl CH₃ 4-Br CH₃ 4-F CH₃ 4-CH₃ CH₃ 4-CF₃ CH₃ 4-alkynyl CH₃ 4-CN CH₃ 4-SO₂N(CH₃)₂ CH₃ 4-CONHCH₃ CH₃ 4-F-3-Br CH₃ 4-F-3-I CH₃ 4-F-3-CH₃ CH₃ 4-F-3-CF₃ CH₃ 4-F-3-alkynyl CH₃ 4-F-3-CN CH₃ 4-F-3-NO₂ CH₃ 4-F-3-OCH₃ CH₃ 4-F-3-C(O)CH₃ CH₃ 4-F-3-SO₂CH₃ CH₃ 4-F-3-S(O)CH₃ CH₃ 4-F-3-CO₂CH₃ CH₃ 4-F-3-SO₂NHCH₃ CH₃ 4-F-3-CO₂CH₂CH₃ CH₃ 4-F-3-SO₂N(CH₃)₂ CH₃ 4-F-3-CONHCH₃ CH₃ 4-F-3-CON(CH₃)₂ CH₃ 4-F-3-CON(CH₃)₂ CH₃ 4-F-3-Cl CH₃ 3-F-4-F CH₃ 2-SO₂CH₃ CH₃ 3-COOH CH₃ 4-COOH CH₃ 2-C(O)OCH₃ CH₃ 2-I CH₃ 2-Cl CH₃ 2-Br CH₃ 2-F CH₃ 2-CH₃ CH₃ 2-CH₃ CH₃ 2-alkynyl CH₃ 2-CN CH₃ 2-NO₂ CH₃ 2-OCH₃ CH₃ 2-C(O)CH₃ Et 3-Cl Et 3-Br Et 3-F Et 3-CH₃ Et 3-CF₃ Et 3-alkynyl Et 3-CN Et 3-NO₂ Et 3-OCH₃ Et 3-C(O)CH₃ Et 3-SO₂CH₃ Et 3-S(O)CH₃ Et 3-CO₂CH₃ Et 3-SO₂NHCH₃ Et 3-CO₂CH₂CH₃ Et 3-SO₂N(CH₃)₂ Et 3-CONHCH₃ Et 3-CON(CH₃)₂ Et 4-CON(CH₃)₂ Et 3-I Et 4-Cl Et 4-Br Et 4-F Et 4-CH₃ Et 4-CF₃ Et 4-alkynyl Et 4-CN Et 4-NO₂ Et 4-OCH₃ Et 4-C(O)CH₃ Et 4-SO₂CH₃ Et 4-S(O)CH₃ Et 4-CO₂CH₃ Et 4-SO₂NHCH₃ Et 4-CO₂CH₂CH₃ Et 4-SO₂N(CH₃)₂ Et 4-CONHCH₃ Et 4-F-3-Br Et 4-F-3-I Et 4-F-3-CH₃ Et 4-F-3-CF₃ Et 4-F-3-alkynyl Et 4-F-3-CN Et 4-F-3-NO₂ Et 4-F-3-OCH₃ Et 4-F-3-C(O)CH₃ Et 4-F-3-SO₂CH₃ Et 4-F-3-S(O)CH₃ Et 4-F-3-CO₂CH₃ Et 4-F-3-SO₂NHCH₃ Et 4-F-3-CO₂CH₂CH₃ Et 4-F-3-SO₂N(CH₃)₂ Et 4-F-3-CONHCH₃ Et 4-F-3-CON(CH₃)₂ Et H Et 4-F-3-Cl Et 3-F-4-F Et 2-SO₂CH₃ Et 3-COOH Et 4-COOH Et 2-C(O)OCH₃ Et 2-I Et 2-Cl Et 2-Br Et 2-F Et 2-CH₃ Et 2-CH₃ Et 2-alkynyl Et 2-CN Et 2-NO₂ Et 2-OCH₃ Et 2-C(O)CH₃ (CH₂)₂OMe 3-CON(CH₃)₂ (CH₂)₂OMe H (CH₂)₂OMe 3-Cl (CH₂)₂OMe 3-Br (CH₂)₂OMe 3-F (CH₂)₂OMe 3-CH₃ (CH₂)₂OMe 3-CF₃ (CH₂)₂OMe 3-alkynyl (CH₂)₂OMe 3-CN (CH₂)₂OMe 3-NO₂ (CH₂)₂OMe 3-OCH₃ (CH₂)₂OMe 3-C(O)CH₃ (CH₂)₂OMe 3-SO₂CH₃ (CH₂)₂OMe 3-S(O)CH₃ (CH₂)₂OMe 3-CO₂CH₃ (CH₂)₂OMe 3-SO₂NHCH₃ (CH₂)₂OMe 3-CO₂CH₂CH₃ (CH₂)₂OMe 3-SO₂N(CH₃)₂ (CH₂)₂OMe 3-CONHCH₃ (CH₂)₂OMe 3-I (CH₂)₂OMe 4-Cl (CH₂)₂OMe 4-Br (CH₂)₂OMe 4-F (CH₂)₂OMe 4-CH₃ (CH₂)₂OMe 4-CF₃ (CH₂)₂OMe 4-alkynyl (CH₂)₂OMe 4-CN (CH₂)₂OMe 4-NO₂ (CH₂)₂OMe 4-OCH₃ (CH₂)₂OMe 4-C(O)CH₃ (CH₂)₂OMe 4-SO₂CH₃ (CH₂)₂OMe 4-S(O)CH₃ (CH₂)₂OMe 4-CO₂CH₃ (CH₂)₂OMe 4-SO₂NHCH₃ (CH₂)₂OMe 4-CO₂CH₂CH₃ (CH₂)₂OMe 4-SO₂N(CH₃)₂ (CH₂)₂OMe 4-CONHCH₃ (CH₂)₂OMe 4-CON(CH₃) (CH₂)₂OMe 4-F-3-CON(CH₃)₂ (CH₂)₂OMe 4-F-3-Br (CH₂)₂OMe 4-F-3-I (CH₂)₂OMe 4-F-3-CH₃ (CH₂)₂OMe 4-F-3-CF₃ (CH₂)₂OMe 4-F-3-alkynyl (CH₂)₂OMe 4-F-3-CN (CH₂)₂OMe 4-F-3-NO₂ (CH₂)₂OMe 4-F-3-OCH₃ (CH₂)₂OMe 4-F-3-C(O)CH₃ (CH₂)₂OMe 4-F-3-SO₂CH₃ (CH₂)₂OMe 4-F-3-S(O)CH₃ (CH₂)₂OMe 4-F-3-CO₂CH₃ (CH₂)₂OMe 4-F-3-SO₂NHCH₃ (CH₂)₂OMe 4-F-3-CO₂CH₂CH₃ (CH₂)₂OMe 4-F-3-SO₂N(CH₃)₂ (CH₂)₂OMe 4-F-3-CONHCH₃ (CH₂)₂OMe 4-F-3-Cl (CH₂)₂OMe 3-F-4-F (CH₂)₂OMe 2-SO₂CH₃ (CH₂)₂OMe 3-COOH (CH₂)₂OMe 4-COOH (CH₂)₂OMe 2-C(O)OCH₃ (CH₂)₂OMe 2-I (CH₂)₂OMe 2-Cl (CH₂)₂OMe 2-Br (CH₂)₂OMe 2-F (CH₂)₂OMe 2-CH₃ (CH₂)₂OMe 2-CH₃ (CH₂)₂OMe 2-alkynyl (CH₂)₂OMe 2-CN (CH₂)₂OMe 2-NO₂ (CH₂)₂OMe 2-OCH₃ (CH₂)₂OMe 2-C(O)CH₃ (CH₂)₂OMe 3-Cl (CH₂)₂OMe 3-Br (CH₂)₂OMe 3-F (CH₂)₂OMe 3-CH₃ (CH₂)₂OMe 3-CF₃ (CH₂)₂OMe 3-alkynyl (CH₂)₂OMe 3-CN (CH₂)₂OMe 3-NO₂ (CH₂)₂OMe 3-OCH₃ (CH₂)₂OMe 3-C(O)CH₃ (CH₂)₂OMe 3-SO₂CH₃ (CH₂)₂OMe 3-S(O)CH₃ (CH₂)₂OMe 3-CO₂CH₃ (CH₂)₂OMe 3-SO₂NHCH₃ (CH₂)₂OMe 3-CO₂CH₂CH₃ (CH₂)₂OMe 3-SO₂N(CH₃)₂ (CH₂)₂OMe 3-CONHCH₃ (CH₂)₂OMe 3-CON(CH₃)₂ (CH₂)₂OMe 4-CON(CH₃)₂ (CH₂)₂OMe 3-I (CH₂)₂OMe 4-Cl (CH₂)₂OMe 4-Br (CH₂)₂OMe 4-F (CH₂)₂OMe 4-CH₃ (CH₂)₂OMe 4-CF₃ (CH₂)₂OMe 4-alkynyl (CH₂)₂OMe 4-CN (CH₂)₂OMe 4-NO₂ (CH₂)₂OMe 4-OCH₃ (CH₂)₂OMe 4-C(O)CH₃ (CH₂)₂OMe 4-SO₂CH₃ (CH₂)₂OMe 4-S(O)CH₃ (CH₂)₂OMe 4-CO₂CH₃ (CH₂)₂OMe 4-SO₂NHCH₃ (CH₂)₂OMe 4-CO₂CH₂CH₃ (CH₂)₂OMe 4-SO₂N(CH₃)₂ (CH₂)₂OMe 4-CONHCH₃ (CH₂)₂OMe 4-F-3-alkynyl (CH₂)₂OMe 4-F-3-CN (CH₂)₂OMe 4-F-3-Br (CH₂)₂OMe 4-F-3-I (CH₂)₂OMe 4-F-3-CH₃ (CH₂)₂OMe 4-F-3-CF₃ (CH₂)₂OMe 4-F-3-NO₂ (CH₂)₂OMe 4-F-3-OCH₃ (CH₂)₂OMe 4-F-3-C(O)CH₃ (CH₂)₂OMe 4-F-3-SO₂CH₃ (CH₂)₂OMe 4-F-3-S(O)CH₃ (CH₂)₂OMe 4-F-3-CO₂CH₃ (CH₂)₂OMe 4-F-3-SO₂NHCH₃ (CH₂)₂OMe 4-F-3-CO₂CH₂CH₃ (CH₂)₂OMe 4-F-3-SO₂N(CH₃)₂ (CH₂)₂OMe 4-F-3-CONHCH₃ (CH₂)₂OMe 4-F-3-CON(CH₃)₂ (CH₂)₂OMe 4-F-3-Cl (CH₂)₂OMe 3-F-4-F (CH₂)₂OMe 2-SO₂CH₃ (CH₂)₂OMe H (CH₂)₂OMe 3-COOH (CH₂)₂OMe 4-COOH (CH₂)₂OMe 2-C(O)OCH₃ (CH₂)₂OMe 2-I (CH₂)₂OMe 2-Cl (CH₂)₂OMe 2-Br (CH₂)₂OMe 2-F (CH₂)₂OMe 2-CH₃ (CH₂)₂OMe 2-CF₃ (CH₂)₂OMe 2-alkynyl (CH₂)₂OMe 2-CN (CH₂)₂OMe 2-NO₂ (CH₂)₂OMe 2-OCH₃ (CH₂)₂OMe 2-C(O)CH₃ (CH₂)₂OH 3-I (CH₂)₂OH H (CH₂)₂OH 3-Cl (CH₂)₂OH 3-Br (CH₂)₂OH 3-F (CH₂)₂OH 3-CH₃ (CH₂)₂OH 3-CF₃ (CH₂)₂OH 3-alkynyl (CH₂)₂OH 3-CN (CH₂)₂OH 3-NO₂ (CH₂)₂OH 3-OCH₃ (CH₂)₂OH 3-C(O)CH₃ (CH₂)₂OH 3-CO₂CH₃ (CH₂)₂OH 3-S(O)CH₃ (CH₂)₂OH 3-CO₂CH₂CH₃ (CH₂)₂OH 3-SO₂NHCH₃ (CH₂)₂OH 3-CONHCH₃ (CH₂)₂OH 3-SO₂N(CH₃)₂ (CH₂)₂OH 4-CON(CH₃)₂ (CH₂)₂OH 3-CON(CH₃)₂ (CH₂)₂OH 4-Cl (CH₂)₂OH 4-Br (CH₂)₂OH 4-F (CH₂)₂OH 4-CH₃ (CH₂)₂OH 4-CF₃ (CH₂)₂OH 4-alkynyl (CH₂)₂OH 4-CN (CH₂)₂OH 4-NO₂ (CH₂)₂OH 4-OCH₃ (CH₂)₂OH 4-C(O)CH₃ (CH₂)₂OH 4-SO₂CH₃ (CH₂)₂OH 4-S(O)CH₃ (CH₂)₂OH 4-CO₂CH₃ (CH₂)₂OH 4-SO₂NHCH₃ (CH₂)₂OH 4-CO₂CH₂CH₃ (CH₂)₂OH 4-SO₂N(CH₃)₂ (CH₂)₂OH 4-CONHCH₃ (CH₂)₂OH 4-CON(CH₃)₂ (CH₂)₂OH 4-F-3-CON(CH₃)₂ (CH₂)₂OH 4-F-3-Br (CH₂)₂OH 4-F-3-I (CH₂)₂OH 4-F-3-CH₃ (CH₂)₂OH 4-F-3-CF₃ (CH₂)₂OH 4-F-3-alkynyl (CH₂)₂OH 4-F-3-CN (CH₂)₂OH 4-F-3-NO₂ (CH₂)₂OH 4-F-3-OCH₃ (CH₂)₂OH 4-F-3-C(O)CH₃ (CH₂)₂OH 4-F-3-SO₂CH₃ (CH₂)₂OH 4-F-3-SO₂NHCH₃ (CH₂)₂OH 4-F-3-CO₂CH₂CH₃ (CH₂)₂OH 4-F-3-SO₂N(CH₃)₂ (CH₂)₂OH 4-F-3-CONHCH₃ (CH₂)₂OH 4-F-3-Cl (CH₂)₂OH 3-F-4-F (CH₂)₂OH H (CH₂)₂OH 3-COOH (CH₂)₂OH 4-COOH (CH₂)₂OH 2-C(O)OCH₃ (CH₂)₂OH 2-I (CH₂)₂OH 2-Cl (CH₂)₂OH 2-Br (CH₂)₂OH 2-F (CH₂)₂OH 2-CH₃ (CH₂)₂OH 2-CH₃ (CH₂)₂OH 2-alkynyl (CH₂)₂OH 2-CN (CH₂)₂OH 2-NO₂ (CH₂)₂OH 2-OCH₃ (CH₂)₂OH 2-C(O)CH₃ (CH₂)₂OH 2-SO₂CH₃ CH₃ 4-NO₂ CH₃ 4-OCH₃ CH₃ 4-C(O)CH₃ CH₃ 4-SO₂CH₃ CH₃ 4-S(O)CH₃ CH₃ 4-CO₂CH₃ CH₃ 4-SO₂NHCH₃ CH₃ 4-CO₂CH₂CH₃

TABLE 2 Examples of R⁵ in the compound of formula (I) suitable for being used as medical active ingredient R⁵ R⁵ R⁵ R⁵ F OH OCH₃ OCH₂CH₃ O(CH₂)₂OMe O(CH₂)₃OMe O(CH₂)₂OH OPr-n OPr-i O(CH₂)₃OH O(CH₂)₄OMe OBu-n O(CH₂)₃NMe₂ O(CH₂)₂NMe₂ O(CH₂)₃NEt₂ O(CH₂)₂NEt₂ O(CH₂)₃(1-morpholinyl) O(CH₂)₃(1-pyrrolinyl) O(CH₂)₂(1-morpholinyl) O(CH₂)₂(1-pyrrolinyl) O(CH₂)₃(1-imidazolyl) O(CH₂)₃(1-piperidyl) O(CH₂)₂(1-imidazolyl) O(CH₂)₂(1-imidazolyl) O(CH₂)₄(1-morpholinyl) O(CH₂)₄(1-pyrrolyl) O(CH₂)₄(1-imidazolyl) H O(CH₂)₄(1-piperidyl) CH₃ NMe₂ NHC(O)Me N(Me)C(O)Me OCF₃ OCF₂CH₃

The invention further relates to a pharmaceutical preparation comprising a pharmaceutically acceptable excipient and a compound of formula (I),

wherein X represents N, C—CN or CH; Y represents CH₂, S, O or N—R⁹; R¹, R³, R⁷ and R⁸ independently represent H, CF₃, or C₁₋₆alkyl; R² represents a group selected from formula (II), (III), (IV), (V), (VI), (VII) or (VIII);

R⁴ and R⁶ independently represent H, C₁₋₆alkyl, OC₁₋₆alkyl, OH, F, Cl, Br, OCF₃, or trifluoromethyl; R⁵ is independently at each occurrence selected from H, F, C₁₋₆alkyl, OH, OC₁₋₆alkyl, OCF₃, O(CH₂)₂₋₄OCF₃, OCF₂CH₃, NH₂, NH(C₁₋₆alkyl), N(C₁₋₆alkyl)₂, 1-pyrrolinyl, 1-piperidyl, 4-morpholinyl, F, Cl, Br, trifluoromethyl, O(CH₂)₂₋₄OC₁₋₆alkyl, O(CH₂)₂₋₄NH(C₁₋₆alkyl), O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄O, (1-piperidyl)(CH₂)₂₋₄O, (4-morpholinyl)(CH₂)₂₋₄O, NHC(O)H, NHC(O)(C₁₋₆alkyl), N(C₁₋₆ alkyl)C(O)(C₁₋₆alkyl), O(CH₂)₂₋₄OH, N(C₁₋₆alkyl)C(O)O(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)OH, NHC(O)O(C₁₋₆alkyl), OC(O)NH(C₁₋₆alkyl), OC(O)N(C₁₋₆alkyl)₂, (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-imidazolyl)(CH₂)₂₋₄O, (4-imidazolyl)(CH₂)₂₋₄OC(O), (pyrazolyl)(CH₂)₂₋₄O, (triazolyl)(CH₂)₂₋₄OC(O), or Ar(CH₂)₁₋₄O; R⁹ is independently at each occurrence selected from H, C₁₋₆alkyl, CF₃, CF₂CH₃, (CH₂)₂₋₄OH, (CH₂)₁₋₄OC₁₋₆alkyl, (CH₂)₁₋₄ NH(C₁₋₆alkyl), (CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₄, (1-piperidyl)(CH₂)₁₋₄, (4-morpholinyl)(CH₂)₁₋₄, C(O)C₁₋₆alkyl, C(O)(CH₂)₁₋₄OH, C(O)(CH₂)₁₋₄OC₁₋₆alkyl, C(O)(CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₆C(O), (1-piperidyl)(CH₂)₁₋₆C(O), (4-morpholinyl)(CH₂)₁₋₄C(O), C(O)OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄ N(C₁₋₆alkyl)₂, C(O)O(CH₂)₂₋₄NH(C₁₋₆alkyl), (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (CH₂)₁₋₄C(O)OC₁₋₆alkyl, or Ar(CH₂)₁₋₄; R¹⁰ represents H, C₁₋₆ alkyl, or F; R¹¹ and R¹² represent independently at each occurrence H, F, Cl, Br, I, CN, NO₂, CF₃, OH, NH₂, C₁₋₄ alkyl, OC₁₋₄ alkyl, OCF₃, OCF₂CH₃, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, OC(O)C₁₋₄ alkyl, NHC(O)H, NHC(O)C₁₋₄ alkyl, N(C₁₋₄ alkyl)C(O)C₁₋₄ alkyl, C(O)OC₁₋₄ alkyl, C(O)NHC₁₋₄ alkyl, C(O)N(C₁₋₄ alkyl)₂, COOH, C(O)C₁₋₄ alkyl, S(O)C₁₋₄ alkyl, SO₂C₁₋₄ alkyl, SO₂NHC₁₋₄ alkyl, or SO₂N(C₁₋₄ alkyl)₂; A, B independently represent aromatic ring; Ar is phenyl, substituted phenyl or pyridyl; D represents O, S, NH, or methylene; m and n independently represent an integer from 0 to 4; z is 1, or 2, and t and u independently represent an integer from 0 to 4.

The pharmaceutical preparation is formulated for a mode of administration selected from oral, intravenous, intraperitoneal, subcutaneous, intramuscular, nasal, ocular, pulmonary, anal, vaginal, or epidermal.

In other embodiments, this invention relates to treating or preventing physiological disorder caused by EGFR or Her-2 overexpression in mammals comprising administering a compound or a preparation of the invention described herein, the disorder including but not limited to breast cancer, kidney cancer, bladder cancer, oral cancer, laryngeal cancer, esophageal cancer, gastric cancer, colorectal cancer, ovarian cancer, lung cancer, or head and neck cancer. In addition, the application relates to treating or preventing a physiological disorder by inhibiting EGFR-TK activity in mammals, the disorder including but not limited to psoriasis, pneumonia, hepatitis, nephritis, pancreatitis, or diabetes.

In other aspects of the invention provided is a method for preparing a compound of formula (I),

wherein X represents N, C—CN or CH; Y represents CH₂, S, O or N—R⁹; R¹, R³, R⁷ and R⁸ independently represent H, CF₃, or C₁₋₆alkyl; R² represents a group selected from formula (II), (III), (IV), (V), (VI), (VII) or (VIII);

R⁴ and R⁶ independently represent H, C₁₋₆alkyl, OC₁₋₆alkyl, OH, F, Cl, Br, OCF₃, or trifluoromethyl; R⁵ is independently at each occurrence selected from H, F, C₁₋₆alkyl, OH, OC₁₋₆alkyl, OCF₃, O(CH₂)₂₋₄OCF₃, OCF₂CH₃, NH₂, NH(C₁₋₆alkyl), N(C₁₋₆alkyl)₂, 1-pyrrolinyl, 1-piperidyl, 4-morpholinyl, F, Cl, Br, trifluoromethyl, O(CH₂)₂₋₄OC₁₋₆alkyl, O(CH₂)₂₋₄NH(C₁₋₆alkyl), O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄O, (1-piperidyl)(CH₂)₂₋₄O, (4-morpholinyl)(CH₂)₂₋₄O, NHC(O)H, NHC(O)(C₁₋₆alky), N(C₁₋₆alkyl)C(O)(C₁₋₆alkyl), O(CH₂)₂₋₄OH, N(C₁₋₆alkyl)C(O)O(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)OH, NHC(O)O(C₁₋₆alkyl), OC(O)NH(C₁₋₆alkyl), OC(O)N(C₁₋₆alkyl)₂, (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-imidazolyl)(CH₂)₂₋₄O, (4-imidazolyl)(CH₂)₂₋₄OC(O), (pyrazolyl)(CH₂)₂₋₄O, (triazolyl)(CH₂)₂₋₄OC(O), or Ar(CH₂)₁₋₄O; R⁹ is independently at each occurrence selected from H, C₁₋₆alkyl, CF₃, CF₂CH₃, (CH₂)₂₋₄OH, (CH₂)₁₋₄OC₁₋₆alkyl, (CH₂)₁₋₄NH(C₁₋₆alkyl), (CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₄, (1-piperidyl)(CH₂)₁₋₄, (4-morpholinyl)(CH₂)₁₋₄, C(O)C₁₋₆alkyl, C(O)(CH₂)₁₋₄OH, C(O)(CH₂)₁₋₄OC₁₋₆alkyl, C(O)(CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₆C(O), (1-piperidyl)(CH₂)₁₋₆C(O), (4-morpholinyl)(CH₂)₁₋₄C(O), C(O)OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, C(O)O(CH₂)₂₋₄NH(C₁₋₆alkyl), (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (CH₂)₁₋₄C(O)OC₁₋₆alkyl, or Ar(CH₂)₁₋₄; R¹⁰ represents H, C₁₋₆ alkyl, or F; R¹¹ and R¹² represent independently at each occurrence H, F, Cl, Br, I, CN, NO₂, CF₃, OH NH₂, C₁₋₄ alkyl, OC₁₋₄ alkyl, OCF₃, OCF₂CH₃, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, OC(O)C₁₋₄ alkyl, NHC(O)H, NHC(O)C₁₋₄ alkyl, N(C₁₋₄ alkyl)C(O)C₁₋₄ alkyl, C(O)OC₁₋₄ alkyl, C(O)NHC₁₋₄ alkyl, C(O)N(C₁₋₄ alkyl), COOH, C(O)C₁₋₄ alkyl, S(O)C₁₋₄ alkyl, SO₂C₁₋₄ alkyl, SO₂NHC₁₋₄ alkyl, or SO₂N(C₁₋₄ alkyl); A, B independently represent aromatic ring; Ar is phenyl, substituted phenyl or pyridyl; D represents O, S, NH, or methylene; m and n independently represent an integer from 0 to 4; z is 1, or 2, and t and u independently represent an integer from 1 to 4; the method comprising the steps of:

1) contacting a compound of formula (XI)

with (R¹⁵)(R¹³)P(O)CH(R⁸)COOR¹⁴ or Ar₃P═CR⁸CO₂R¹⁴ to yield a compound of formula (IX)

wherein Y represents CH₂, S, O, or N—R⁹ except NH; R⁸ independently represent H, CF₃, or C₁₋₆alkyl; R⁹ is independently at each occurrence selected from H, C₁₋₆alkyl, CF₃, CF₂CH₃, (CH₂)₂₋₄OH, (CH₂)₁₋₄OC₁₋₆alkyl, (CH₂)₁₋₄NH(C₁₋₆alkyl), (CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₄, (1-piperidyl)(CH₂)₁₋₄, (4-morpholinyl)(CH₂)₁₋₄, C(O)C₁₋₆alkyl, C(O)(CH₂)₁₋₄OH, C(O)(CH₂)₁₋₄OC₁₋₆alkyl, C(O)(CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₆C(O), (1-piperidyl)(CH₂)₁₋₆C(O), (4-morpholinyl)(CH₂)₁₋₄C(O), C(O)OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (CH₂)₁₋₄C(O)OC₁₋₆alkyl, or Ar(CH₂)₁₋₄; R¹³ and R¹⁵ are independently C₁₋₄alkyl, OC₁₋₄-alkyl, phenyl, substituted phenyl, phenoxy, or substituted phenoxy; R¹¹ represents C₁₋₅alkyl; Ar is phenyl or substituted phenyl; and m and n independently represent an integer from 0 to 4.

2) the compound of formula (IX) can be firstly transformed into active ester, acyl chloride, acyl imidazole or mixed anhydride and then contacted with the compound of formula (X) to yield a compound of formula (I),

wherein X, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹², A B, D, Ar, m, n, z, t and u are as in claim 1; Y represents N—R⁹; and R⁹ is not H. And tertiary amines, such as triethylamine, N-methylmorpholine, trimethylamine, pyridine or substituted pyridine can be used to accelerate the reaction. When the compound of formula (IX) is transformed into acyl chloride, thionyl chloride, phosphorus trichloride, phosphorus pentachloride, phosphorus oxychloride, oxalyl chloride, or cyanuric chloride can be used as chlorinating agents.

Optionally, the compound of formula (IX) can be firstly transformed into anhydride and then contacted with the compound of formula (X), and pyridine or substituted pyridine such as DMAP can be used as catalyst to accelerate the reaction.

3) transforming the compound of formula (I), wherein X, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹², A, B, D, Ar, m, n, z, t, and u are as in claim 1; Y represents N—R⁹; and R⁹ represents (CH₃)₃OC(O); obtained in step 2) in acidic conditions or pyrrolytic into the compound of formula (XII)

R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹², A, B, D, X, Ar, m, n, z, t and u are as defined in claim 1;

Acidic condition can be achieved by the use of trifluoroacetate acid, hydrochloric acid, sulfonic acid or an acetyl chloride—alcohol system.

4) contacting the compound of formula (XII) as defined in step 3) with R⁹-LG to obtain the compound of formula (I), wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², A B, D, X, Y, Ar, m, n, z, t, and u are as defined in claim 1, and LG represents Cl, Br, I, OMs, or OTs.

In step 4, organic base such as triethylamine, trimethylamine, pyridine, substituted pyridine or inorganic base such as sodium carbonate, potassium carbonate can be used to accelerate the reaction, and solvent suitable for the reaction comprises acetonitrile, dimethylformamide, dimethylacetamide, tetrahydrofuran, or ethylene glycol dimethyl ether.

The present invention teaches an irreversible EGF receptor tyrosine kinase inhibitor featuring a unique chemical structure and low reactivity-high inhibitory activity against EGF receptor tyrosine kinase. In one embodiment of the invention, the compound exhibits good inhibitory activity against A431 cell self-phosphorylation stimulated by EGF, and exhibits a certain growth inhibitory activity against the cell strain, and has a good anti-tumor effect in A431 tumor animal pathological model.

DETAILED DESCRIPTION OF THE INVENTION

Inhibition Experiment of Cellular Epidermal Growth Factor Receptor Tyrosine Kinase

(EGFR-TK)

1) A431 cells were cultured in a medium which was prepared by adding 10% FCS into another medium comprising 50% DMEM and 50% F12.

2) A431 cells grown in six-well plates were cultured in a serum-free medium for 24 hours. During the 24 hour period the medium was replenished once after 12 hours.

3) A solution containing a compound to be assessed was added the A431 cells and the cells were cultured for 2 hours, supplemented twice by a medium free of the compound, and then EGF (100 ng/well) was added, and cultured for 5 minutes.

4) A431 cell homogenate was prepared by Laemili buffer which comprised 2% sodium dodecyl sulfonate (SDS), 5% 2-mercaptoethanol, 10% glycerol and 5 mM Tris (pH 6.8).

5) The A431 cell homogenate was heated for 5 minutes at 100° C.

6) Proteins in the A431 cell homogenates were separated by PAGE and transferred onto a nitrocellulose membrane, and an infrared reading was obtained.

7) Calculation of percent inhibition:

% inhibition=100−[reading by infrared reader (sample)/reading by infrared reader (blank)]×100

Partial one-time measurement results for a single concentration are listed in Table 3 (preliminary selection). EC₅₀ measurement results of representative compounds are listed in Table 4.

TABLE 3 Inhibitory activity (percent inhibition) of representative compounds with concentration of 3 μM against A431 cells EGFR-TK phosphorylation stimulated by EGF Inhi- Inhi- [nhi- bition bition bition Percent Percent Percent Compound (%) Compound (%) Compound (%) Example 1 NA Example 3 85 Example 4 78 Example 5 73 Example 6 24 Example 7 65 Example 8 NA Example 30 55 Example 31 33 Example 32 87 Example 33 94 Example 34 68 Example 35 23 Example 36 57 Example 37 82 Example 38 94 Example 40 89 Example 41 71 Example 43 91 Example 50 95 Example 51 94 Example 72 97 Example 73 82 Example 105 44 Example 107 52 Example 110 59 Example 118 41 Example 132 64 Example 134 59 Example 141 91 Example 143 96 Example 144 89 Example 150 46 Note: NA = No activity

TABLE 4 Inhibitory activity (EC₅₀) of representative compounds against A431 cells EGFR-TK phosphorylation stimulated by EGF EC₅₀ EC₅₀ EC₅₀ Compound (μM) Compound (μM) Compound (μM) Example 3 0.15 Example 4 0.58 Example 7 0.4 Example 32 0.09 Example 33 0.038 Example 34 0.76 Example 36 0.98 Example 41 0.30 Example 65 0.23 Example 84 0.013 Example 85 13 Example 110 0.9 Example 141 0.28 Example 143 0.16

Irreversible Inhibition of Cellular Epidermal Growth Factor Receptor Tyrosine Kinase

(EGFR-TK)

1) A431 cells were cultured in a medium prepared by adding 10% FCS into another medium comprising 50% DMEM and 50% F12.

2) The A431 cells grown in six-well plates were cultured in a serum-free medium for 24 hours, during the period the medium was replenished once after 12 hours.

3) A solution containing a compound to be assessed was added to the A431 cells and cultured for 2 hours, supplemented twice by a medium free of the compound, and then EGF (100 ng/well) was added, and cultured for 5 minutes.

4) A431 cell homogenate was prepared by Laemili buffer which comprised 2% sodium dodecyl sulfonate (SDS), 5% 2-mercaptoethanol, 10% glycerol and 5 mM Tris; the pH value is 6.8.

5) The A431 cell homogenate was heated for 5 minutes at 100° C.

6) Proteins in the A431 cell homogenates were separated by PAGE, transferred onto a nitrocellulose membrane, and an infrared reading was obtained.

7) Calculation of percent inhibition:

% inhibition=100−[reading by infrared reader (medicine)/reading by infrared reader (blank)]×100

8) Calculation of percent recovery:

% recovery=100−% inhibition

Parts of the results are listed in Table 5.

TABLE 5 Activity of representative compounds against A431 cells EGFR-TK phosphorylation stimulated by EGF Inhibition Recovery Compound EC₅₀(μM) percent(%) percent(%) Activity Example 32 0.09  78 22 Irreversible inhibitor Example 33 0.038 89 11 Irreversible inhibitor Example 84 0.013 14 86 Reversible inhibitor

Following literature procedured, inhibitory activity of representative compounds against BT474 cells Her-2 receptor TK phosphorylation stimulated by Her-2 was measured, and partial results are listed in Table 6.

TABLE 6 Inhibitory activity of representative compounds against BT474 cells Her-2 receptor TK phosphorylation stimulated by Her-2 EC₅₀ EC₅₀ EC₅₀ Compound (μM) Compound (μM) Compound (μM) Example 43 0.35 Example 72 0.82 Example 73 1.7  Example 105 0.48 Example 108 0.18 Example 150 0.26

Cell Growth Inhibition Assay (MTS Assay)

1. Cell Strain and Reagents

A431: human epithelial adenocarcinoma cell strain; LoVo: human colorectal cancer cell strain; BT474: breast cancer; SK-Br-3: breast cancer; SIT solution (SIGMA); RPMI1640 culture solution; phosphoric acid buffer; Dimethyl Sulphoxide (DMSO); MTS solution (Promega), 96 well cell culture plate, representative anti-cancer compounds.

2. Measurement

The above-mentioned cells were cultured for several days (RPMI 1640, 10% of bovine serum), collected and suspended in RPMI1640-SIT serum-free medium, placed into a 96-well cell culture plate with each well containing 20,000 cells/100 pt. The cells were cultured overnight under the condition of 5% CO₂ and 37° C. The next day, representative anti-cancer compounds (between 3 and 10 mM) were dissolved by dimethyl sulphoxide (DMSO) as a mother solution. Adriamycin was used as positive control, DMSO was used as negative control. According to experimental design, the mother solution was diluted and added to the 96 well cell culture plate, cultured for 48 hours under the condition of 5% CO₂ and 37° C. Subsequently, 20 μL of MTS solution was added to each well of the 96 well cell culture plate and cultured for another 2 to 4 hours under the condition of 5% CO₂ and 37° C. Absorbance was read at 490 nm wavelength, and converted into cell survival rate.

Calculation of percent inhibition:

% inhibition=100−[reading of infrared reader (medicine)/reading of infrared reader (blank)]×100

For each concentration, there two measurements were taken and the average was obtained. Partial results are listed in Tables 7, 8 and 9.

TABLE 7 Growth inhibition activity (EC₅₀) of representative compounds against A431 cells EC₅₀ EC₅₀ EC₅₀ Compound (μM) Compound (μM) Compound (μM) Example 3 2 Example 4 1.8 Example 7 5 Example 32 0.6 Example 33 0.10 Example 34 13 Example 36 30 Example 38 0.014 Example 41 1.5 Example 42 0.12 Example 43 0.11 Example 50 0.15 Example 51 0.12 Example 72 0.09 Example 73 0.63 Example 84 0.30 Example 85 35 Example 108 3.0 Example 118 1.9 Example 134 0.9 Example 143 0.25 Example 154 0.11 Tarceva 0.45 Lapatinib 1.19

TABLE 8 Growth inhibition activity (EC₅₀) (in μM) of representative compounds against BT474 and SK-Br-3 cells Compound BT474 SK-Br-3 Example 43 0.61 0.52 Example 72 1.31 0.80 Example 73 21.48 2.31 Example 108 1.57 0.53 Lapatinib 0.12 0.07

TABLE 9 Growth inhibition activity (EC₅₀) (in μM) of representative compounds against colorectal cancer LoVo cells EC₅₀ EC₅₀ EC₅₀ Compound (μM) Compound (μM) Compound (μM) Example 42 3 Example 43 1.5 Example 38 1.6 Example 51 7.6 Example 72 1.8 Example 73 8.0 Example 108 7.0 Example 154 3.1 Adriamycin 1.5

A431 Cell Growth Inhibition Assay (MTT Assay) Materials and Reagents

A431, an epidermoid carcinoma cell line; The Cell Bank, Committee on Type Culture Collection Chinese Academy of Science, Shanghai.

MTT, (Amresco cat.no 0793) 5 mg/mL, dissolved in phosphate buffered saline (PBS), non-sterile. Store at −20° C.

DMSO, (Analytical reagent) Tianjin Guangfu Fine Chemical Research Institute.

DMEM, (Gibco, cat.no 12800-058 lot.1272041), Add 2.2 g/L sodium bicarbonate (Sangon, cat.no 0865) and 25 mM HEPEs (Bio.Basic. Inc., cat.no HB0264), then filter the medium with 0.22 μm filter membrane after modulating pH to 7.00. Store at 4° C.

F12, (Gibco, cat.no 21700-026 lot.268207), Add 2.2 g/L sodium bicarbonate and 25 mM HEPEs, then filter the medium with 0.22 μm filter membrane after modulating pH to 7.00. store at 4° C.

Trypsin solution, (Invitrogen, cat.no 27250018), 0.25% (w/v), dissolved in phosphate buffered saline (PBS), non-sterile; then add 0.53 mM EDTA after filtering with 0.22 μm filter membrane. Store at 4° C.

PBS, (pH 7.2˜7.4), NaCl, 8.00 g. KCl, 0.20 g. Na₂HPO₄, 1.17 g. KH₂PO₄, 0.20 g. Dissolved in 1 L ddH₂O, autoclaved for sterilization at 121° C. for 20 minutes. Store at 4° C.

FBS, (similar standard fetal bovine serum, directly use after being thawed out) Lanzhou National Hyclone Bio-Engineering Co., Ltd. lot. 20090521.

Equipment

96-well clear flat-bottom cell-culture plates, Corning, cat.no 3599

Inverted biologic microscope, Model XD-101, Nanjing Jiangnan Novel Optics Co., Ltd.

CO₂ Incubator, W/C₄₅₁ S/N 309493-2488, Thermo-Fisher Scientific Corp.

Biologic Clean Beach, Model DL-CJ-2N, Harbin Donglian Haer Instrument Manufacturing Co., Ltd.

Microplate reader, Model 680, Beijing Yuanye Bio Co., Ltd.

Autoclave, Model YXQG02, Shandong Ande Medical Technology Co., Ltd.

Plate shaker, Mode MM-I, Shanghai Yarong Biochemistry Instrument Factory.

Procedure

Cell Complete Growth Medium Preparation

Mix prepared medium DMEM and F12 in the proportion of 1:1, then add FBS to a final concentration of 10%.

Compound Preparation

Dissolved the dried compound sample with 100% DMSO to 2 mM. Then diluted the dissolved compound to 20 μM with cell complete growth medium. For further IC50 determination, made a threefold dilution from 20 μM to 3.04 nM in complete growth medium containing 1% DMSO.

Cell Preparation

Prior to the assay, cultured the A431 to logarithmic phase, and then removed medium from cell monolayers and wash the cells once with sterilized PBS. Aspriated the PBS and added 2 mL trypsin solution to cover the cell growth surface, removed 1 mL trypsin solution after soaking about 1 minute. Transferred the cell-culture plate to CO₂ incubator; incubated at 37° C. for 8 minutes to allow cells to dissociate. After the cells detached, added 4 mL complete growth medium containing FBS with pipette to disperse them off and mixed gently to obtain a homogeneous cell suspension. Aspirated some of the cell suspension to a sterilized polypropylene tube, and determined the cell concentration by counting in a hematocytometer chamber under a microscope. Adjusted the cell concentration with growth medium to obtain 2.5×10⁴ cells per milliliter.

Cell Seeding

Added 100 μL adjusted cell suspension to the 96-well cell-culture plate and occasionally mixed the cell suspension during the seeding process. After seeding cells, incubated the plate at 37° C. overnight with 5% CO₂ in the CO₂ incubator for cell attachment.

Exposed the Cell to the Compound

After the cell attachment, added 100 μL prepared compound solutions to the corresponding wells (add PBS to the ambient wells of the plate). The final compound concentrations ranged from 10 μM to 1.52 nM. Incubated the plate at 37° C. with 5% CO₂ for 72 hours in the CO₂ incubator.

MTT Reaction.

After the exposure to the compound, removed the cell culture supernatant. Then added 100 μL 0.5 mg/mL MTT solution which dissolved in the growth medium without FBS. Incubated the plate at 37° C. with 5% CO₂ for another 4 hours to allow the MTT reaction to proceed.

Detection

After the MTT reaction, discarded the MTT reaction solution. Added 100 μL DMSO to each well, and the plate was agitated on the plate shaker for several minutes to dissolve the formazan. Then, detected the absorbance at 490 nm using microplate reader.

TABLE 10 Inhibitory activity (percent inhibition) of representative compounds with concentration of 3 μM against A431 cells Inhi- Inhi- Inhi- bition bition bition Percent Percent Percent Compound (%) Compound (%) Compound (%) Example 143 70 Example 145 49 Example 146 52 Example 149 92 Example 150 95 Example 152 95 Example 155 90 Example 156 89 Example 157 85 Example 158 90 Example 159 83 Example 161 49 Example 162 41 Example 163 40 Example 165 53 Example 166 49 Example 167 45 Example 168 41 Example 169 92 Example 170 88 Example 171 86 Example 172 84 Example 173 87 Example 178 88 Example 179 90 Example 180 92 Example 181 94 Example 182 90 Example 183 90 Example 190 91 Example 191 93 Example 192 93 Example 193 90 Example 194 89

TABLE 11 Growth inhibition activity (EC₅₀) (in μM) of representative compounds against A431 cells Compound EC₅₀(μM) Compound EC₅₀(μM) Example 143 1.45 Example 145 3.4  Example 150 0.17 Example 152 0.14

BT-474 Cell Growth Inhibition Assay (SRB Assay)

Main Materials

BT-474 human breast cancer cell lines were kindly provided by Dr. Changnian Liu, Pharmaron Beijing Co., Ltd.

EMEM: purchased from Invitrogen Corporation., catalog number 41500-034, added 2.2 g/l NaHCO3, 25 mM HEPEs, adjusted pH to 7.0, stored at 4° C.

Similar standard fatal bovine serum (sFBS): purchased from Lanzhou National Hyclone Bio-Engineering Co., Ltd., China.

Cell culture medium: 90% EMEM and 10% sFBS, stored at 4° C.

PBS: 8 g/l NaCl, 0.2 g/l KCl, 1.17 g/lNa₂HPO₄, 0.2 g/l KH₂PO₄, adjusted pH to 7.2-7.4;

Trypsin/EDTA solution: 0.25% (wt/vol) Trypsin (Invitrogen Corporation, catalog number 27250018) in PBS, added 0.53 mM EDTA, stored at 4° C.;

1% (wt/vol) acetic acid.

SRB: purchased from Sigma-Aldrich, catalog number S9012-5 g; dissolved in 1% acetic acid as a 0.4% (wt/vol) solution, stored at 4° C., protected from light.

50% (wt/vol) TCA (Trichloroacetic acid).

10 mM unbuffered Tris base solution.

96-well cell culture plates: Corning, catalog number 3599.

25 cm̂2 cell culture flasks: Corning, catalog number 430168.

Main Equipment

Super-clean chamber: Model DL-CJ-2N, Harbin Donglian Haer Instrument Manufacturing Co., Ltd.

Inverted Microscope: Model XD-101, JiangNanGuangXueYiQiChang, Nanjing, China.

CO2 incubator: Model 311, Thermo Scientific.

Autoclave: Model YXQG02, Shandong AnDe Medical Technology Co.,Ltd.

Micro-plate reader: Model 680, Bio-Rad.

Automated 96-well plate washer: Model 1575, Bio-Rad.

Analytical balance: Model BT125D, Sartorius, Max120 g, d=0.01 mg (41 g), 0.1 mg (120 g).

Plate shaker, Mode MM-I, Shanghai Yarong Biochemistry Instrument Factory

Methods

All work was performed under sterile working conditions.

BT-474 cells were cultured in 37° C., 5% CO2, saturated humidity until logarithmic phase. Discarded culture medium, washed cells once by PBS. Added 1 ml Trypsin/EDTA solution, stood at 37° C. for 5 min, allowed the cells to detach. Added culture medium, adjusted the cells density to 1×10̂5 cells/ml.

Day 0, added 100 μl/well cells suspension to 96-well cell culture plates. Incubated overnight to let the cells attach completely.

Day 1, compounds (2 mM in DMSO as stock solution) was diluted to 20 μM in EMEM. Then a fourfold serial dilution was made. These diluted compounds were made as 10× reaction solutions, and the concentration of DMSO was kept at 1%.

Added 80 μl culture medium and 20 μl 10× compound reaction solution to the testing wells, or vehicle control to the control wells. Co-incubated cells with compounds for another 72 h.

Day 3, fixed cellular protein by the addition of 100 μl/well of 10% TCA (diluting from 50% TCA) at 4° C. for 1 h. Rinsed TCA using plate washer, and washed five times using distilled water. Removed the residual wash solution with a piece of absorbent paper. Added 100 μl/well 0.4% SRB solution, allowed a 15-30 min staining period. Removed the SRB, and washed the culture plates five times using 1% acetic acid. Removed the residual wash solution with a piece of absorbent paper. Air-dried the culture plates, dissolved the protein-bound dye with 100 μl/well of 10 mM Tris base solution. Shook the plates until the dye was dissolved completely. Measured the OD value by using the micro-plate reader at the wavelength of 570 nm.

% inhibition ratio=[1−(OD _(sample)−mean OD_(positive control))/(mean OD_(positive control)−mean OD negative control]×100, where the OD_(sample) was cells growing with compounds, the OD_(positive) control was cells growing with vehicle, OD_(negative control) was blank well with vehicle.

TABLE 12 Inhibitory activity (percent inhibition) of representative compounds with concentration of 3 μM against BT474 cells Inhi- Inhi- Inhi- bition bition bition Percent Percent Percent Compound (%) Compound (%) Compound (%) Example 143 55 Example 145 80 Example 146 85 Example 149 53 Example 150 56 Example 152 59 Example 155 58 Example 156 60 Example 157 59 Example 158 57 Example 159 53 Example 161 90 Example 162 91 Example 163 87 Example 165 87 Example 166 85 Example 167 84 Example 168 89 Example 169 58 Example 170 56 Example 171 60 Example 172 61 Example 173 44 Example 197 82 Example 198 86 Example 199 87 Example 200 90 Example 201 89 Example 202 92 Example 203 86 Example 206 80 Example 208 83 Example 209 78 Example 211 81

EXAMPLES Intermediate 1a: Tert-butyl 4-oxopiperidine-1-carboxylate

Hydrated 4-piperidone hydrochloride (8.65 g), BOC₂O (12.2 g), NaHCO₃ (8.8 g), and NaCl (11.2 g) were dissolved in a mixture of tetrahydrofuran (80 mL) and water (80 mL), stirred at room temperature, and allowed to stand overnight for layer separation. The water layer was extracted once with chloroform. The organic phases were combined, washed once with brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was evaporated to give the title compound as a white solid (11.35 g).

Intermediate 1b: Tert-butyl 3-oxopyrrolidine-1-carboxylate

The title compound was prepared following the procedure for preparation of intermediate 1a except that 3-oxopyrrolidine hydrochloride was substituted for 4-piperidone hydrochloride.

Intermediate 1c: 1-(2-methoxyethyl)piperidin-4-one

Hydrated 4-piperidone hydrochloride (8.65 g), 1-iodo-2-methoxyethane (12.58 g), and K₂CO₃ (15.55 g) were dissolved in a mixture of tetrahydrofuran (80 mL) and water (80 mL), stirred at room temperature, and allowed to stand overnight for layer separation. The water layer was extracted once with chloroform. The organic phases were combined, washed once with brine, dried over anhydrous magnesium sulfate, and filtered. The filtrate was evaporated in vacuo to give the title compound as an oil.

Intermediate 2a: Tert-butyl 4-((methoxycarbonyl)methylene)piperidine-1-carboxylate

Sodium hydroxide (4.56 g, 0.114 mol) was dissolved in ethanol (210 mL), and trimethyl phosphonoacetate (11.4 g, 0.062 mol) added with stirring. The mixture was stirred for 30 min at room temperature. Tert-butyl 4-oxopiperidine-1-carboxylate (11.35 g, 0.057 mol) was added with stirring at room temperature, and the reaction was allowed to stand overnight. Then, the mixture was acidified with diluted hydrochloric acid until the pH was 4, filtered, concentrated, and partitioned into water and chloroform. Phases were separated. The aqueous phase was extracted once with chloroform. Chloroform phases were combined, washed once with brine, dried over anhydrous magnesium sulfate, and filtered. The filtrate was evaporated in vacuo to give the title compound.

Intermediate 2b: Methyl 2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetate

The title compound was prepared following the procedure for the preparation of intermediate 2a except that 1-(2-methoxyethyl)piperidin-4-one was substituted for 4-oxopiperidine-1-carboxylate.

Intermediate 2c: (E/Z)-tert-butyl 3-((methoxycarbonyl)methylene)pyrrolidine-1-carboxylate

The title compound was prepared following the procedure for the preparation of intermediate 2a except that tert-butyl 3-oxopyrrolidine-1-carboxylate was substituted for 4-oxopiperidine-1-carboxylate.

Intermediate 3a: 2-(1-(tert-butoxycarbonyl)piperidin-4-ylidene)acetic Acid

The above obtained tert-butyl 4-((methoxycarbonyl)methylene)piperidine-1-carboxylate was dissolved in a mixture of tetrahydrofuran (60 mL) and methanol (60 mL). 1N lithium hydroxide (60 mL) was added with stirring at room temperature, and the reaction mixture was allowed to stand overnight. Then, the mixture was extracted three times with dichloromethane. The organic phase was separated. The aqueous phase was acidified with 1N hydrochloric acid until the pH value was about 4 and extracted three times with dichloromethane. The organic phases were combined, washed once with brine, dried over anhydrous magnesium sulfate, and filtered. The filtrate was evaporated in vacuo to give the title compound.

Intermediate 3b: 2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetic Acid.

The title compound was prepared following the procedure for the preparation of intermediate 3a except that methyl 2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetate was substituted for tert-butyl 4-((methoxycarbonyl)methylene)piperidine-1-carboxylate.

Intermediate 3c: (E/Z)-2-(1-(tert-butoxycarbonyl)pyrrolidin-3-ylidene)acetic Acid

The title compound was prepared following the procedure for the preparation of the intermediate 3a except that (E/Z)-tert-butyl 3-((methoxycarbonyl)methylene)pyrrolidine-1-carboxylate was substituted for tert-butyl 4-((methoxycarbonyl)methylene)piperidine-1-carboxylate.

Intermediate 4a: N⁴-(3-ethynylphenyl)quinazoline-4,6-diamine

2 g of iron powder was immersed in diluted hydrochloric acid for 30 min, filtered, and washed with water. The washed iron powder, 0.1 g of N-(3-ethynylphenyl)-6-nitroquinazolin-4-amine, 25 mL of ethanol-water solution (water:ethanol=1:2), and 0.3 mL of acetic acid were added into a four-neck flask, and refluxed for one hour with mechanical stirring. After reaction completion, the mixture was cooled to room temperature, filtered, concentrated and ethyl acetate was added. The mixture was washed three times with hydrochloric acid. The aqueous layer was combined and made alkaline with Na₂CO₃ until the pH was about 9. The aqueous layer was extracted three times with ethyl acetate. All organic phases were combined, washed once with brine, dried over anhydrous magnesium sulfate, and filtered. The filtrate was evaporated in vacuo to give the title compound.

Intermediates 4b-4-r were prepared following the procedure for the preparation of intermediate 4a.

Intermediate 4b: N⁴-(4-(benzyloxy)-3-chlorophenyl)quinazoline-4,6-diamine

Intermediate 4c: N⁴-(4-(3-chlorobenzyloxy)-3-chlorophenyl)quinazoline-4,6-diamine

Intermediate 4d: N⁴-(4-(3-bromobenzyloxy)-3-chlorophenyl)quinazoline-4,6-diamine

Intermediate 4e: N⁴-(4-(3-methoxybenzyloxy)-3-chlorophenyl)quinazoline-4,6-diamine

Intermediate 4f: N⁴-(4-(3-ethoxybenzyloxy)-3-chlorophenyl)quinazoline-4,6-diamine

Intermediate 4g: N⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)quinazoline-4,6-diamine

Intermediate 4h: N⁴-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-7-fluoroquinazoline-4,6-diamine

Intermediate 41: N⁴-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-7-methoxyquinazoline-4,6-diamine

Intermediate 4j: N⁴-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-7-ethoxyquinazoline-4,6-diamine

Intermediate 4k: N⁴-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-7-(2-methoxyethoxy)quinazoline-4,6-diamine

Intermediate 41: N⁴-(4-(3-chlorobenzyloxy)-3-chlorophenyl)-7-methoxyquinazoline-4,6-diamine

Intermediate 4m: N⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-methoxyquinazoline-4,6-diamine

Intermediate 4n: N⁴-(1-benzyl-1H-indol-5-yl)quinazoline-4,6-diamine

Intermediate 4o: N⁴-(1-(3-fluorobenzyl)-1H-indol-5-yl)-7-methoxyquinazoline-4,6-diamine

Intermediate 4p: N⁴-(1-benzyl-1H-indol-5-yl)-7-(2-methoxyethoxy)quinazoline-4,6-diamine

Intermediate 4q: 7-ethoxy-N⁴-(3-methoxy-4-phenoxyphenyl)quinazoline-4,6-diamine

Intermediate 4r: 7-ethoxy-N⁴-(4-(4-fluorophenoxy)-3-methoxyphenyl)quinazoline-4,6-diamine

Example 1 Tert-butyl 4-((4-(3-ethynylphenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate

1 g of 2-(1-(tert-butyloxycarbonyl)piperidine-4-ylidene)acetic acid was added to 20 mL of anhydrous THF in a one-neck flask (100 mL). The solution was stirred and cooled on salt-ice bath. Then, 0.6 mL of isobutyl chloroformate and 0.5 mL of N-methylmorpholine were added, and the reaction mixture was let stir for 20 min 1.046 g of N⁴-(3-ethynylphenyl)quinazoline-4,6-diamine dissolved in 10 mL of pyridine (dried over molecular sieves) and 0.4 mL of N-methylmorpholine were added to the reaction mixture on an ice bath with stirring. After reaction completion, the solvent was evaporated in vacuo and the remaining residue was partitioned with chloroform and water. The chloroform layer was washed once with brine, dried over anhydrous magnesium sulfate, filtered, and evaporated in vacuo to give a crude product. The crude product was recrystallized from isopropanol. MS (EI) 482 M⁺.

Example 2 N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide trifluoroacetate

Tert-buty-((4-(3-ethynylphenylamino)quinazolin-6-yl-aminocarbonyl)-methylene)piperidine-1-carboxylic ester (92 mg, 0.38 mmol) was dissolved in 10 mL of 20% anhydrous TFA/DCM solution and stirred at room temperature for 2 hours, evaporated in vacuo, and vacuum dried to give the tile compound as a whitish foam. MS: 384 (M+1).

Example 3 N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide

N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide trifluoroacetate was dissolved in ethyl acetate. The mixture was washed once with saturated Na₂CO₃ and once with brine, dried over anhydrous magnesium sulfate, filtered, and evaporated in vacuo to give the title product. MS (EI) 384 (M+1).

Example 4 N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide (20 mg, 0.046 mmol), methyl iodide (8.0 mg, 0.056 mmol), anhydrous potassium carbonate (17 mg), and acetonitrile (5 mL) were placed in a one-neck flask (50 mL). The reaction mixture was stirred at room temperature for 24 hours. After reaction completion, the solution was filtered, and evaporated in vacuo to give a solid. The solid was purified by TLC (silica gel plate, thickness 5 mm, chloroform:methanol=95:5). MS: 398 (M+1).

The compounds of Example 5-8 were prepared following the procedure of Example 4.

Example 5

-   2-(1-Ethylpiperidin-4-ylidene)-N-(4-(3-ethynylphenylamino)quinazolin-6-yl)acetamide.     MS: 412 (M+1).

Example 6

-   2-(1-benzylpiperidin-4-ylidene)-N-(4-(3-ethynylphenylamino)quinazolin-6-yl)acetamide.     MS: 474 (M+1).

Example 7

-   N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 440 (M−1).

Example 8

-   Methyl     2-(4-((4-(3-ethynylphenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidin-1-yl)acetate.     MS: 454 (M⁺).

Example 9

-   N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(1-isopropylpiperidin-4-ylidene)acetamide.     MS: 426 (M+1).

Example 10

-   N-(4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(1-(2-hydroxyethyl)piperidin-4-ylidene)acetamide.     MS: 428 (M+1).

The compounds of Examples 11-29 were prepared following the procedure of Example 1.

Example 11

-   Tert-butyl     4-((4-(phenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 459 (M⁺).

Example 12

-   Tert-butyl     4-((4-(3-chloro-4-fluorophenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 511 (M⁺).

Example 13

-   Tert-butyl     4-((4-(3-bromophenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 539 (M+1).

Example 14

-   Tert-butyl     4-((4-((S)-1-phenylethylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 487 (M⁺).

Example 15

-   Tert-butyl     4-((4-((R)-1-phenylethylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 487 (M⁺).

Example 16

-   Tert-butyl     4-((4-(3-chlorophenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 493 (M⁺).

Example 17

-   Tert-butyl     4-((4-(3-chlorophenylamino)-7-fluoroquinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 511 (M⁺).

Example 18

-   Tert-butyl     4-((4-(3-bromophenylamino)-7-methoxyquinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 568 (M+1).

Example 19

-   Tert-butyl     4-((4-(3-bromophenylamino)-7-ethoxyquinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 582 (M+1).

Example 20

-   Tert-butyl     4-((7-(2-methoxyethoxy)-4-(3-bromophenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 612 (M+1).

Example 21

-   Tert-butyl     4-((4-(1H-indol-5-ylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 498 (M⁺).

Example 22

-   Tert-butyl     4-((4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 512 (M⁺).

Example 23

-   Tert-butyl     4-((4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 541 (M⁺).

Example 24

-   Tert-butyl     4-((4-(1H-indol-5-ylamino)-7-methoxyquinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 528 (M⁺).

Example 25

-   Tert-butyl     4-((4-(3-bromophenylamino)-7-(3-methoxypropoxy)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 626 (M⁺).

Example 26

-   Tert-butyl     4-((4-(3-bromophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 681 (M⁺).

Example 27

-   Tert-butyl     4-((7-(2-methoxyethoxy)-4-(3-ethynylphenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 557 (M+1).

Example 28

-   Tert-butyl     4-((7-(2-methoxyethoxy)-4-(3-chloro-4-fluorophenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 585 (M⁺).

Example 29

-   Tert-butyl     4-((4-(1H-indol-5-ylamino)-7-(2-methoxyethoxy)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate.     MS: 572 (M⁺).

Following the procedure of Examples 2 and 3, the compounds of Examples 30-50 were prepared.

Example 30

-   N-(4-(3-chlorophenylamino)-7-fluoroquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 411 (M+1).

Example 31

-   N-(4-(phenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 359 (M+1).

Example 32

-   N-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 410 (M⁺).

Example 33

-   N-(4-(3-bromophenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 438 (M⁺).

Example 34

-   N-(4-((S)-1-phenylethylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.MS:     387 (M⁺).

Example 35

-   N-(4-((R)-1-phenylethylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 387 (M⁺).

Example 36

-   N-(4-(3-chlorophenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 393 (M⁺).

Example 37

-   N-(4-(3-bromophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 581 (M⁺).

Example 38

-   N-(4-(3-bromophenylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 467 (M⁺).

Example 39

-   N-(4-(3-bromophenylamino)-7-ethoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 482 (M⁺).

Example 40

-   N-(4-(3-bromophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 512 (M+1).

Example 41

-   N-(4-(1H-indol-5-ylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 398 (M+1).

Example 42

-   N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 413 (M⁺).

Example 43

-   N-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 441 (M+1).

Example 44

-   N-(4-(1H-indol-5-ylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 428 (M+1).

Example 45

-   (S)—N-(7-methoxy-4-(1-phenylethylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 417 (M⁺).

Example 46

-   (R)—N-(7-methoxy-4-(1-phenylethylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 417 (M⁺).

Example 47

-   N-(4-(3-ethynylphenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 457 (M⁺).

Example 48

-   N-(4-(3-chloro-4-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 485 (M⁺).

Example 49

-   N-(4-(3-ethynylphenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 526 (M+1).

Example 50

-   N-(4-(3-ethynylphenylamino)-7-(3-methoxypropoxy)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 471 (M+1).

Following the procedure of Example 4, the compounds of Examples 51-83 were prepared.

Example 51

-   N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 427 (M+1).

Example 52

-   N-(7-ethoxy-4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide.     MS: 455 (M⁺).

Example 53

-   2-(1-ethylpiperidin-4-ylidene)-N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)acetamide.     MS: 441 (M⁺).

Example 54

-   N-(7-ethoxy-4-(3-ethynylphenylamino)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 441 (M⁺).

Example 55

-   N-(4-(3-bromophenylamino)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 452 (M⁺).

Example 56

-   N-(4-(3-bromophenylamino)quinazolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide.     MS: 466 (M+1).

Example 57

-   N-(4-(3-bromophenylamino)quinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 496 (M+1).

Example 58

-   N-(4-(3-bromophenylamino)-7-methoxyquinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 482 (M+1).

Example 59

-   N-(4-(3-bromophenylamino)-7-methoxyquinazolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide.     MS: 496 (M+1).

Example 60

-   N-(4-(3-bromophenylamino)-7-methoxyquinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 526 (M⁺).

Example 61

-   N-(4-(3-bromophenylamino)-7-methoxyquinazolin-6-yl)-2-(1-(3-methoxypropyl)piperidin-4-ylidene)acetamide.     MS: 540 (M⁺).

Example 62

-   N-(4-(3-bromophenylamino)-7-ethoxyquinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 496 (M+1).

Example 63

-   N-(4-(3-bromophenylamino)-7-ethoxyquinazolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide.     MS: 510 (M⁺).

Example 64

-   N-(4-(3-bromophenylamino)-7-ethoxyquinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 540 (M⁺).

Example 65

-   N-(4-(3-bromophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 526 (M⁺).

Example 66

-   N-(4-(3-bromophenylamino)-7-(3-methoxypropoxy)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 540 (M⁺).

Example 67

-   N-(4-(3-bromophenylamino)-7-(3-(dimethylamino)propoxy)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 552 (M⁺).

Example 68

-   N-(4-(3-bromophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 595 (M+1).

Example 69

-   N-(4-(3-chlorophenylamino)-7-fluoroquinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 425 (M⁺).

Example 70

-   N-(4-(3-chlorophenylamino)-7-fluoroquinazolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide.     MS: 439 (M⁺).

Example 71

-   N-(4-(3-chlorophenylamino)-7-fluoroquinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 469 (M⁺).

Example 72

-   N-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 455 (M⁺).

Example 73

-   N-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide     MS: 499 (M⁺)

Example 74

-   N-(4-(3-chloro-4-fluorophenylamino)quinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 469 (M⁺).

Example 75

-   N-(4-(1H-indol-5-ylamino)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 412 (M+1).

Example 76

-   N-(4-(1H-indol-5-ylamino)quinazolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide.     MS: 426 (M+1).

Example 77

-   N-(4-(1H-indol-5-ylamino)quinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 456 (M⁺).

Example 78

-   (S)-2-(1-methylpiperidin-4-ylidene)-N-(4-(1-phenylethylamino)quinazolin-6-yl)acetamide.     MS: 401 (M⁺).

Example 79

-   (S)-2-(1-ethylpiperidin-4-ylidene)-N-(4-(1-phenylethylamino)quinazolin-6-yl)acetamide.     MS: 415 (M⁺).

Example 80

-   (S)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)-N-(4-(1-phenylethylamino)quinazolin-6-yl)acetamide.     MS: 445 (M⁺).

Example 81

-   (S)—N-(7-(2-methoxyethoxy)-4-(1-phenylethylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 461 (M⁺).

Example 82

-   N-(4-(1H-indol-5-ylamino)-7-(2-methoxyethoxy)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 472 (M+1).

Example 83

-   N-(4-(3-bromophenylamino)quinazolin-6-yl)-2-(pyrrolidin-3-ylidene)acetamide.     MS: 423 (M+1).

Example 84 Comparison Compound A: N-(4-(3-bromophenylamino)quinazolin-6-yl)propionamide

N⁴-(3-bromophenyl)quinazoline-4,6-diamine (100 mg, 0.32 mmol), pyridine (0.3 mL), and DMAP (20 mg) were dissolved in 10 mL of anhydrous THF. The solution was cooled to 5° C. Propionyl chloride (33 mg, 0.35 mmol) was added to the reaction flask dropwise. Ice bath removed was removed, and the reaction mixture was stirred at room temperature and filtered. The filtrate was dried in vacuo to give a yellow solid. The yellow solid was dissolved in ethyl acetate, washed once with saturated Na₂CO₃, then with 10% acetic acid, and then with brine. The organic phase was dried, filtered, and stripped of solvent in vacuo to give a crude product which was purified by TLC to give the title compound as a whitish product.

Example 85 Comparison Compound B: N-(4-(3-bromophenylamino)quinazolin-6-yl)acrylamide

The title compound was prepared following the procedure of Example 84 and substituting acryloyl chloride for propionyl chloride.

Example 86 Comparison Compound C: N-(4-(3-bromophenylamino)quinazolin-6-yl)-3-methylbut-2-enamide

The title compound was prepared following the procedure of Example 84 and substituting 3-methyl-butyl-2-en-acyl chloride for propionyl chloride.

Example 87 N-(7-methoxy-4-(2-phenylcyclopropylamino)quinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

1) Preparation of 2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetyl Chloride Hydrochloride

2.4 g of 2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetic acid was dissolved in 20 mL of thionyl chloride, refluxed for 2 hours, evaporated in vacuo to remove thionyl chloride and give a solid product.

2) Preparation of N-(7-methoxy-4-(2-phenylcyclopropylamino) quinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

Following the procedure of Example 84, the title compound was prepared by reacting 2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetyl chloride hydrochloride with N⁴-(7-methoxy-4-(2-phenylcyclopropyl)quinazolin-4,6-diamine

Example 88 N¹-(4-(3-bromophenylamino)quinazolin-6-yl)-N⁴-(2-(2-(dimethylamino)ethoxy)ethyl)fumaramide

79 mg of N⁴-(3-bromophenyl)quinazoline-4,6-diamine, 39 mg of maleic anhydride, and 15 mL of THF were placed in a one-neck flask (50 mL) and refluxed. After the reaction was completed, the reaction mixture was evaporated in vacuo and purified by thin layer chromatography.

The pure product was dissolved in anhydrous THF, and 2-(2-aminoethoxy)ethanol was added. The solution was cooled in ice bath. Subsequently, THF solution containing DCC was added dropwise, ice bath was removed, and the reaction mixture was refluxed for a day. After the reaction was completed, the solution was cooled to room temperature, filtered, and evaporated in vacuo to give crude title product.

105 mg of the crude product was dissolved in 20 mL pyridine, and 400 mg of 4-methylbenzene-1-sulfonyl chloride added with stirring at room temperature. After the reaction was completed, the solvent was evaporated in vacuo and the residue was dissolved in ethyl acetate, washed once with saturated Na₂CO₃, once with 1N HCl, and once with brine. The organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated in vacuo to give a product.

The product was dissolved in 10 mL pyridine, and dimethylamine added with stirring at room temparature. After the reaction was completed, the solvent was evaporated in vacuo and the title purified by thin layer chromatography. MS (EI) 528 M⁺.

Example 89 N-(4-(3-bromophenylamino)quinazolin-6-yl)-2-(1-(2-(2-(2-hydroxyethoxy)ethylamino)acetyl)piperidin-4-ylidene)acetamide

40 mg of N-(4-(3-bromophenylamino)quinazolin-6-yl)-2-(piperidine-4-ylidene)acetamide and 10 ml of THF were added in a one-mouth flask (50 ml), cooled in ice bath, 0.01 mL of 2-chloroacetyl chloride, and 0.02 mL of triethylamine (dried over molecular sieves) were added with stirring at room temperature. After the reaction was completed, the solvent was evaporated in vacuo, the residue was dissolved in ethyl acetate, washed three times with water and once with brine, dried over anhydrous magnesium sulfate, filtered, and evaporated in vacuo to give a crude product (30 mg).

The crude product was dissolved in 10 mL of acetonitrile, and 7.3 mg (0.07 mmol) of 2-(2-aminoethoxy)ethanol and 0.02 mL of triethylamine (dried over molecular sieves) were added with stirring at room temperature. After the reaction was completed, the solvent was evaporated in vacuo and the remaining residue was purified by thin layer chromatography. MS (EI) 581 M⁺.

Compounds in Examples 90-101 were prepared using literature procedures.

Example 90 N⁴-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-7-(3-morpholinopropoxy)quinazoline-4,6-diamine

Example 91 N⁴-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-7-(3-methoxypropoxy)quinazoline-4,6-diamine

Example 92 N⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-ethoxyquinazoline-4,6-diamine

Example 93 N⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-methoxyquinazoline-4,6-diamine

Example 94 N⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-fluoroquinazoline-4,6-diamine

Example 95 N⁴-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)quinazoline-4,6-diamine

Example 96 7-methoxy-N⁴-(3-methoxy-4-phenoxyphenyl)quinazoline-4,6-diamine

Example 97 7-methoxy-N⁴-(4-(3-methoxyphenoxy)phenyl)quinazoline-4,6-diamine

Example 98 N⁴-(2-chloro-4-(pyridin-2-ylmethoxy)phenyl)-7-methoxyquinazoline-4,6-diamine

Example 99 N⁴-(4-(benzyloxy)-3-chlorophenyl)-7-methoxyquinazoline-4,6-diamine

Example 100 N⁴-(4-(3-chlorobenzyloxy)-3-fluorophenyl)-7-methoxyquinazoline-4,6-diamine

Example 101 N⁴-(4-(3-chloro-4-fluorobenzyloxy)phenyl)-7-methoxyquinazoline-4,6-diamine

Example 102 Tert-butyl 4-((4-(4-((pyridin-2-yl)methoxy)-3-chlorophenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-1-carboxylate

1 g of 2-(1-(tert-butyloxycarbonyl)piperidine-4-ylidene)acetic acid and 20 mL of anhydrous THF were placed in a one-neck flask (100 mL), dissolved in stirring, and cooled on a salt-ice bath. Then, 0.6 mL of isobutyl chloroformate and 0.5 mL of N-methylmorpholine were added, stirring for 20 mins. Then, 1.046 g of N⁴-(4-3-chloro-(pyridin-2-ylmethoxy)phenyl)quinazoline-4,6-diamine dissolved in 10 mL of pyridine (dried over molecular sieves), and 0.4 mL of N-methylmorpholine were added with stirring to the reaction flask which was previously cooled on an ice bath. After the reaction was completed, the solvent was evaporated in vacuo and the crude product was partitioned with chloroform and water. The chloroform layer was washed once with saturated brine, dried over anhydrous magnesium sulfate, filtered, and evaporated in vacuo to give the crude title product which was recrystallized from isopropanol. MS (EI) 601 M⁺.

Example 103 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide trifluoroacetate

-   Tert-butyl-4-((4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl-aminocarbonyl)-methylene)piperidine-1-carboxylic     ester (92 mg, 0.38 mmol) was dissolved in 10 mL of 20% anhydrous     TFA/DCM solution with stirring at room temperature for 2 hours,     evaporated in vacuo, and vacuum dried to give the title product as a     whitish foam solid. MS: 501 (M+1).

Example 104 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide

N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide trifluoroacetate was dissolved in ethyl acetate, washed once with saturated Na₂CO₃, and once with brine, dried over anhydrous magnesium sulfate, filtered, and evaporated in vacuo to give the title product. MS (EI) 501 (M+1).

Compounds of Examples 105-115 were prepared following the procedure of Example 104.

Example 105

-   N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 548 (M+1).

Example 106

-   N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-7-(3-methoxypropoxy)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 605 (M⁺).

Example 107

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-ethoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 544 (M⁺).

Example 108

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 531 (M+1).

Example 109

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-fluoroquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 519 (M+1).

Example 110

-   N-(7-methoxy-4-(3-methoxy-4-phenoxyphenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 512 (M+1).

Example 111

-   N-(7-methoxy-4-(4-(3-methoxyphenoxy)phenylamino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 511 (M⁺).

Example 112

-   N-(4-(2-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 531 (M+1).

Example 113

-   N-(4-(4-(benzyloxy)-3-chlorophenylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 531 (M+1).

Example 114

-   N-(4-(4-(3-chlorobenzyloxy)-3-fluorophenylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 547 (M⁺).

Example 115

-   N-(4-(4-(3-chloro-4-fluorobenzyloxy)phenylamino)-7-methoxyquinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 548 (M+1).

Example 116

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl)-2-(1-piperidin-4-ylidene)acetamide (20 mg, 0.046 mmol), methyl iodide (8.0 mg, 0.056 mmol), anhydrous potassium carbonate (17 mg), and acetonitrile (5 mL) were added to a one-neck flask (50 mL), and stirred at room temperature for 24 hours. After the reaction was complete, the solution was filtered, and evaporated in vacuo to give a solid. The solid was purified by TLC (silica gel plate, thickness 5 mm, chloroform:methanol=95:5). MS: 515 (M⁺).

The compounds of Examples 117-118 were prepared following the procedure of Example 116.

Example 117

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-methoxyquinazolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide.     MS: 558 (M⁺).

Example 118

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-methoxyquinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 588 (M⁺).

The compounds of Examples 119-131 were prepared following literature procedures.

Example 119 6-Amino-4-(3-chlorophenylamino)-7-methoxyquinoline-3-carbonitrile

Example 120 6-Amino-4-(3-chloro-4-fluorophenylamino)-7-methoxyquinoline-3-carbonitrile

Example 121 6-Amino-4-(3-ethynylphenylamino)-7-methoxyquinoline-3-carbonitrile

Example 122 6-Amino-4-(3-bromophenylamino)-7-methoxyquinoline-3-carbonitrile

Example 123 6-Amino-4-(3-chloro-4-fluorophenylamino)-7-ethoxyquinoline-3-carbonitrile

Example 124 6-Amino-7-ethoxy-4-(3-ethynylphenylamino)quinoline-3-carbonitrile

Example 125 6-Amino-4-(3-bromophenylamino)-7-ethoxyquinoline-3-carbonitrile

Example 126 6-Amino-4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-methoxyquinoline-3-carbonitrile

Example 127 6-Amino-4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-ethoxyquinoline-3-carbonitrile

Example 128 4-(4-(3-Fluorobenzyloxy)-3-chlorophenylamino)-6-amino-7-methoxyquinoline-3-carb onitrile

Example 129 4-(4-(3-Fluorobenzyloxy)-3-chlorophenylamino)-6-amino-7-ethoxyquinoline-3-carbonitrile

Example 130 6-Amino-4-(4-(3-fluorophenoxy)-3-methoxyphenylamino)-7-methoxyquinoline-3-carbonitrile

Example 131 6-Amino-7-ethoxy-4-(4-(3-fluorophenoxy)-3-methoxyphenylamino)quinoline-3-carbonitrile

Example 132 6-amino-4-(3-chloro-4-fluorophenylamino)quinoline-3-carbonitrile

Example 133 6-amino-4-(3-ethynylphenylamino)quinoline-3-carbonitrile

Example 134 6-amino-4-(3-bromophenylamino)quinoline-3-carbonitrile

Example 135 6-amino-4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinoline-3-carbonitrile

Example 136 4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-6-aminoquinoline-3-carbonitrile

Example 137 6-amino-4-(3-chloro-4-fluorophenylamino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile

Example 138 6-amino-4-(3-ethynylphenylamino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile

Example 139 6-amino-4-(3-bromophenylamino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile

Example 140 6-amino-4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile

Example 141 4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-6-amino-7-(2-methoxyethoxy)quinoline-3-carbonitrile

The compounds of Examples 142-155 were prepared following the procedure of Example 104.

Example 142

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 554 (M+1).

Example 143

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 568 (M+1).

Example 144

-   N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 571 (M⁺).

Example 145

-   N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 586 (M+1).

Example 146

-   N-(4-(3-chloro-4-(3-fluorophenoxy)phenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 558 (M+1).

Example 147

-   N-(4-(3-chlorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 461 (M⁺).

Example 148

-   N-(4-(3-chlorophenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 448 (M+1).

Example 149

-   N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 510 (M+1).

Example 150

-   N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 480 (M+1).

Example 151

-   N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 466 (M+1).

Example 152

-   N-(3-cyano-7-ethoxy-4-(3-ethynylphenylamino)quinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 452 (M+1).

Example 153

-   N-(3-cyano-4-(3-ethynylphenylamino)-7-methoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 438 (M+1).

Example 154

-   N-(4-(3-bromophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 506 (M⁺).

Example 155

-   N-(4-(3-bromophenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide.     MS: 493 (M+1).

The compounds of Examples 156-164 were prepared following the procedure of Example 116.

Example 156

-   N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 494 (M+1).

Example 157

-   N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 537 (M⁺).

Example 158

-   N-(3-cyano-7-ethoxy-4-(3-ethynylphenylamino)quinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 466 (M+1).

Example 159

-   N-(3-cyano-7-ethoxy-4-(3-ethynylphenylamino)quinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 510 (M+1).

Example 160

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 582 (M+1).

Example 161

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 626 (M+1).

Example 162

-   N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide.     MS: 600 (M+1).

Example 163

-   N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 643 (M⁺).

Example 164

-   N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide.     MS: 471 (M⁺).

The compounds of Examples 165-173 were prepared following the procedure of Example 104.

Example 165

-   N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-(2-methoxyetho     xy)quinolin-6-yl)-2-(piperidin-4-ylidene)acetamide

MS: 599 (M+1)

Example 166 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyanoquinolin-6-yl)-2-(ppiperidin-4-ylidene)acetamide

MS:525 (M+1)

Example 167 N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(piperidin-4-ylidene)acetamide

MS:616 (M+1)

Example 168

N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyanoquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide

MS:542 (M+1)

Example 169 N-(3-cyano-4-(3-ethynylphenylamino)-7-(2-methoxyethoxy)quinolin-6-yl)-2-(piperidin-4-ylidene)acetamide

MS:482 (M+1)

Example 170 N-(3-cyano-4-(3-ethynylphenylamino)quinolin-6-yl)-2-(piperidin-4-ylidene)acetamide

MS:408 (M+1)

Example 171 N-(4-(3-bromophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(piperidin-4-ylidene)acetamide

MS:536 (M+1)

Example 172 N-(4-(3-bromophenylamino)-3-cyanoquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide

MS:462 (M+1)

Example 173 N-(4-(3-chloro-4-fluorophenylamino)-3-cyanoquinolin-6-yl)-2-(piperidin-4-ylidene)acetamide

MS:436 (M+1)

The compounds of Examples 174-211 were prepared following the procedure of Example 116.

Example 174 N-(4-(3-chloro-4-fluorophenylamino)-3-cyanoquinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:450 (M+1)

Example 175 N-(4-(3-chloro-4-fluorophenylamino)-3-cyanoquinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS:494 (M+1)

Example 176 N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:480 (M+1)

Example 177 N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS:524 (M+1)

Example 178 N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide

MS:508 (M+1)

Example 179 N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-proplpiperidin-4-ylidene)acetamide

MS:522 (M+1)

Example 180 N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:524 (M+1)

Example 181 N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide

MS:538 (M+1)

Example 182 N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-propylpiperidin-4-ylidene)acetamide

MS:552 (M+1)

Example 183 N-(4-(3-chloro-4-fluorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS:568 (M+1)

Example 184 N-(3-cyano-4-(3-ethynylphenylamino)quinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:422 (M+1)

Example 185 N-(3-cyano-4-(3-ethynylphenylamino)quinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS:466 (M+1)

Example 186 N-(3-cyano-4-(3-ethynylphenylamino)-7-methoxyquinolin-6-yl)-2-(1-(2-methoxy ethyl)piperidin-4-ylidene)acetamide

MS:496 (M+1)

Example 187 N-(3-cyano-4-(3-ethynylphenylamino)-7-methoxyquinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:452 (M+1)

Example 188 N-(3-cyano-7-ethoxy-4-(3-ethynylphenylamino)quinolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide

MS:480 (M+1)

Example 189 N-(3-cyano-7-ethoxy-4-(3-ethynylphenylamino)quinolin-6-yl)-2-(1-propylpiperidin-4-ylidene)acetamide

MS:494 (M+1)

Example 190 N-(3-cyano-4-(3-ethynylphenylamino)-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:496 (M+1)

Example 191 N-(3-cyano-4-(3-ethynylphenylamino)-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide

MS:510 (M+1)

Example 192 N-(3-cyano-4-(3-ethynylphenylamino)-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-propylpiperidin-4-ylidene)acetamide

MS:524 (M+1)

Example 193 N-(3-cyano-4-(3-ethynylphenylamino)-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS:540 (M+1)

Example 194 N-(4-(3-bromophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-m ethylpiperidin-4-ylidene)acetamide

MS:550 (M+1)

Example 195 N-(4-(3-bromophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:520 (M+1)

Example 196 N-(4-(3-bromophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS:594 (M+1)

Example 197 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:569 (M+1)

Example 198 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS:613 (M+1)

Example 199 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide

MS:597 (M+1)

Example 200 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:613 (M+1)

Example 201 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide

MS:627 (M+1)

Example 202 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-propylpiperidin-4-ylidene)acetamide

MS:641 (M+1)

Example 203 N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS:657 (M+1)

Example 204 N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS: 586 (M+1)

Example 205 N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-methoxyquinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS: 630 (M+1)

Example 206 N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide

MS: 614 (M+1)

Example 207 N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-2-(1-propylpiperidin-4-ylidene)acetamide

MS:628 (M+1)

Example 208 N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-methylpiperidin-4-ylidene)acetamide

MS:630 (M+1)

Example 209 N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-ethylpiperidin-4-ylidene)acetamide

MS:644 (M+1)

Example 210 N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-propylpiperidin-4-ylidene)acetamide

MS:658 (M+1)

Example 211 N-(4-(4-(3-fluorobenzyloxy)-3-chlorophenylamino)-3-cyano-7-(2-methoxyethoxy)quinolin-6-yl)-2-(1-(2-methoxyethyl)piperidin-4-ylidene)acetamide

MS:674 (M+1)

While particular embodiments of the invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications may be made without departing from the invention in its broader aspects, and therefore, the aim in the appended claims is to cover all such changes and modifications as fall within the true spirit and scope of the invention. 

1. A method for treating cancer or inhibiting growth of cancer cells comprising administering to a patient mammal in need thereof a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

wherein, X represents C—CN, N, or CH; Y represents CH₂, S, O or N—R⁹; R¹, R³, R⁷ and R⁸ independently represent H, CF₃, or C₁₋₆alkyl; R² represents a substituent of a formula selected from formulas (II), (III), (IV), (V), (VI), (VII), or (VIII);

R⁴ and R⁶ independently represent H, C₁₋₆alkyl, OC₁₋₆alkyl, OH, F, Cl, Br, OCF₃, or trifluoromethyl; R⁵ is independently at each occurrence selected from H, F, C₁₋₆alkyl, OH, OC₁₋₆alkyl, OCF₃, OCF₂CH₃, NH₂, NH(C₁₋₆alkyl), N(C₁₋₆alkyl)₂, 1-pyrrolinyl, 1-piperidyl, 4-morpholinyl, Cl, Br, trifluoromethyl, O(CH₂)₂₋₄OC₁₋₆alkyl, O(CH₂)₂₋₄OCF₃, O(CH₂)₂₋₄NH(C₁₋₆alkyl), O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄O, (1-piperidyl)(CH₂)₂₋₄O, (4-morpholinyl)(CH₂)₂₋₄O, NHC(O)H, NHC(O)(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)(C₁₋₆alkyl), O(CH₂)₂₋₄OH, N(C₁₋₆alkyl)C(O)O(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)OH, NHC(O)O(C₁₋₆alkyl), OC(O)NH(C₁₋₆alkyl), OC(O)N(C₁₋₆alkyl)₂, (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-imidazolyl)(CH₂)₂₋₄O, (pyrazolyl)(CH₂)₂₋₄O, (triazolyl)(CH₂)₂₋₄OC(O), or Ar(CH₂)₁₋₄O; R⁹ is independently at each occurrence selected from H, C₁₋₆alkyl, CF₃, CF₂CH₃, (CH₂)₂₋₄OH, (CH₂)₁₋₄OC₁₋₆alkyl, (CH₂)₁₋₄NH(C₁₋₆alkyl), (CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₄, (1-piperidyl)(CH₂)₁₋₄, (4-morpholinyl)(CH₂)₁₋₄, C(O)C₁₋₆alkyl, C(O)(CH₂)₁₋₄OH, C(O)(CH₂)₁₋₄OC₁₋₆alkyl, C(O)(CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₆C(O), (1-piperidyl)(CH₂)₁₋₆C(O), (4-morpholinyl)(CH₂)₁₋₄C(O), C(O)OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (CH₂)₁₋₄C(O)OC₁₋₆alkyl, or Ar(CH₂)₁₋₄; R¹⁰ represents H, C₁₋₆alkyl, or F; R¹¹ and R¹² represent independently at each occurrence F, Cl, Br, I, CN, NO₂, CF₃, OH, NH₂, C₁₋₄alkyl, OC₁₋₄alkyl, OCF₃, OCF₂CH₃, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, OC(O)C₁₋₄alkyl, NHC(O)H, NHC(O)C₁₋₄alkyl, N(C₁₋₄alkyl)C(O)C₁₋₄alkyl, C(O)OC₁₋₄alkyl, C(O)NHC₁₋₄alkyl, C(O)N(C₁₋₄alkyl)₂, COOH, C(O)C₁₋₄alkyl, S(O)C₁₋₄alkyl, SO₂C₁₋₄alkyl, SO₂NHC₁₋₄alkyl, or SO₂N(C₁₋₄alkyl)₂; A represents a 5-7 membered aromatic ring containing from 0 to 4 heteroatoms selected from N, O or S; or a polycyclic aromatic group consisting of two or three 5 to 7-membered fused rings; B represents a 5-7 membered aromatic ring containing from 0 to 4 heteroatoms selected from N, O or S; or a polycyclic aromatic group consisting of two or three 5 to 7-membered fused rings; Ar is phenyl, pyridyl, or substituted phenyl; D represents O, S, NH, or methylene; m and n independently represent an integer from 0 to 4; z is 1, or 2; and t and u independently represent an integer from 0 to
 4. 2. The method of claim 1, wherein said cancer is breast cancer, kidney cancer, bladder cancer, oral cancer, laryngeal cancer, esophageal cancer, gastric cancer, colorectal cancer, ovarian cancer, lung cancer, or head and neck cancer.
 3. The method of claim 1, wherein EGFR is overexpressed in said cancer cells.
 4. The method of claim 1, wherein Her-2 is overexpressed in said cancer cells.
 5. The method of claim 1, wherein the mammal is human.
 6. The method of claim 1, wherein the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used in a form of pharmaceutical preparation comprising pharmaceutically acceptable excipient.
 7. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

wherein, X represents C—CN, N, or CH; Y represents CH₂, S, O or N—R⁹; R¹, R³, R⁷ and R⁸ independently represent H, CF₃, or C₁₋₆alkyl; R² represents a substituent of a formula selected from formulas (II), (III), (IV), (V), (VI), (VII), or (VIII);

R⁴ and R⁶ independently represent H, C₁₋₆alkyl, OC₁₋₆alkyl, OH, F, Cl, Br, OCF₃, or trifluoromethyl; R⁵ is independently at each occurrence selected from H, F, C₁₋₆alkyl, OH, OC₁₋₆alkyl, OCF₃, OCF₂CH₃, NH₂, NH(C₁₋₆alkyl), N(C₁₋₆alkyl)₂, 1-pyrrolinyl, 1-piperidyl, 4-morpholinyl, Cl, Br, trifluoromethyl, O(CH₂)₂₋₄OC₁₋₆alkyl, O(CH₂)₂₋₄OCF₃, O(CH₂)₂₋₄NH(C₁₋₆alkyl), O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄O, (1-piperidyl)(CH₂)₂₋₄O, (4-morpholinyl)(CH₂)₂₋₄O, NHC(O)H, NHC(O)(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)(C₁₋₆alkyl), O(CH₂)₂₋₄OH, N(C₁₋₆alkyl)C(O)O(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)OH, NHC(O)O(C₁₋₆alkyl), OC(O)NH(C₁₋₆alkyl), OC(O)N(C₁₋₆alkyl)₂, (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-imidazolyl)(CH₂)₂₋₄O, (pyrazolyl)(CH₂)₂₋₄O, (triazolyl)(CH₂)₂₋₄OC(O), or Ar(CH₂)₁₋₄O; R⁹ is independently at each occurrence selected from H, C₁₋₆alkyl, CF₃, CF₂CH₃, (CH₂)₂₋₄OH, (CH₂)₁₋₄OC₁₋₆alkyl, (CH₂)₁₋₄NH(C₁₋₆alkyl), (CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₄, (1-piperidyl)(CH₂)₁₄, (4-morpholinyl)(CH₂)₁₋₄, C(O)C₁₋₆alkyl, C(O)(CH₂)₁₋₄OH, C(O)(CH₂)₁₋₄OC₁₋₆alkyl, C(O)(CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₆C(O), (1-piperidyl)(CH₂)₁₋₆C(O), (4-morpholinyl)(CH₂)₁₋₄C(O), C(O)OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (CH₂)₁₋₄C(O)OC₁₋₆alkyl, or Ar(CH₂)₁₋₄; R¹⁰ represents H, C₁₋₆alkyl, or F; R¹¹ and R¹² represent independently at each occurrence F, Cl, Br, I, CN, NO₂, CF₃, OH, NH₂, C₁₋₄alkyl, OC₁₋₄alkyl, OCF₃, OCF₂CH₃, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, OC(O)C₁₋₄alkyl, NHC(O)H, NHC(O)C₁₋₄alkyl, N(C₁₋₄alkyl)C(O)C₁₋₄alkyl, C(O)OC₁₋₄alkyl, C(O)NHC₁₋₄alkyl, C(O)N(C₁₋₄alkyl)₂, COOH, C(O)C₁₋₄alkyl, S(O)C₁₋₄alkyl, SO₂C₁₋₄alkyl, SO₂NHC₁₋₄alkyl, or SO₂N(C₁₋₄alkyl)₂; A represents a 5-7 membered aromatic ring containing from 0 to 4 heteroatoms selected from N, O or S; or a polycyclic aromatic group consisting of two or three 5 to 7-membered fused rings; B represents a 5-7 membered aromatic ring containing from 0 to 4 heteroatoms selected from N, O or S; or a polycyclic aromatic group consisting of two or three 5 to 7-membered fused rings; Ar is phenyl, pyridyl, or substituted phenyl; D represents O, S, NH, or methylene; m and n independently represent an integer from 0 to 4; z is 1, or 2; and t and u independently represent an integer from 0 to
 4. 8. The method of claim 7, wherein said physiological disorder is psoriasis, pneumonia, hepatitis, nephritis, pancreatitis, diabetes, or cancer.
 9. The method of claim 7, wherein said protein tyrosine kinase is EGFR tyrosine kinase.
 10. The method of claim 7, wherein said protein tyrosine kinase is Her-2 tyrosine kinases.
 11. The method of claim 7, wherein the mammal is human.
 12. The method of claim 7, wherein the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used in a form of pharmaceutical preparation comprising pharmaceutically acceptable excipient.
 13. A method of preparing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

wherein, X represents C—CN, N, or CH; Y represents CH₂, S, O or N—R⁹; R¹, R³, R⁷ and R⁸ independently represent H, CF₃, or C₁₋₆alkyl; R² represents a substituent of a formula selected from formulas (II), (III), (IV), (V), (VI), (VII), or (VIII);

R⁴ and R⁶ independently represent H, C₁₋₆alkyl, OC₁₋₆alkyl, OH, F, Cl, Br, OCF₃, or trifluoromethyl; R⁵ is independently at each occurrence selected from H, F, C₁₋₆alkyl, OH, OC₁₋₆alkyl, OCF₃, OCF₂CH₃, NH₂, NH(C₁₋₆alkyl), N(C₁₋₆alkyl)₂, 1-pyrrolinyl, 1-piperidyl, 4-morpholinyl, Cl, Br, trifluoromethyl, O(CH₂)₂₋₄OC₁₋₆alkyl, O(CH₂)₂₋₄OCF₃, O(CH₂)₂₋₄NH(C₁₋₆alkyl), O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄O, (1-piperidyl)(CH₂)₂₋₄O, (4-morpholinyl)(CH₂)₂₋₄O, NHC(O)H, NHC(O)(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)(C₁₋₆alkyl), O(CH₂)₂₋₄OH, N(C₁₋₆alkyl)C(O)O(C₁₋₆alkyl), N(C₁₋₆alkyl)C(O)OH, NHC(O)O(C₁₋₆alkyl), OC(O)NH(C₁₋₆alkyl), OC(O)N(C₁₋₆alkyl)₂, (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-imidazolyl)(CH₂)₂₋₄O, (pyrazolyl)(CH₂)₂₋₄O, (triazolyl)(CH₂)₂₋₄OC(O), or Ar(CH₂)₁₋₄O; R⁹ is independently at each occurrence selected from H, C₁₋₆alkyl, CF₃, CF₂CH₃, (CH₂)₂₋₄OH, (CH₂)₁₋₄OC₁₋₆alkyl, (CH₂)₁₋₄NH(C₁₋₆alkyl), (CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₄, (1-piperidyl)(CH₂)₁₋₄, (4-morpholinyl)(CH₂)₁₋₄, C(O)C₁₋₆alkyl, C(O)(CH₂)₁₋₄OH, C(O)(CH₂)₁₋₄OC₁₋₆alkyl, C(O)(CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₆C(O), (1-piperidyl)(CH₂)₁₋₆C(O), (4-morpholinyl)(CH₂)₁₋₄C(O), C(O)OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (CH₂)₁₋₄C(O)OC₁₋₆alkyl, or Ar(CH₂)₁₋₄; R¹⁰ represents H, C₁₋₆alkyl, or F; R¹¹ and R¹² represent independently at each occurrence F, Cl, Br, I, CN, NO₂, CF₃, OH, NH₂, C₁₋₄alkyl, OC₁₋₄alkyl, OCF₃, OCF₂CH₃, NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, OC(O)C₁₋₄alkyl, NHC(O)H, NHC(O)C₁₋₄alkyl, N(C₁₋₄alkyl)C(O)C₁₋₄alkyl, C(O)OC₁₋₄alkyl, C(O)NHC₁₋₄alkyl, C(O)N(C₁₋₄alkyl)₂, COOH, C(O)C₁₋₄alkyl, S(O)C₁₋₄alkyl, SO₂C₁₋₄alkyl, SO₂NHC₁₋₄alkyl, or SO₂N(C₁₋₄alkyl)₂; A represents a 5-7 membered aromatic ring containing from 0 to 4 heteroatoms selected from N, O or S; or a polycyclic aromatic group consisting of two or three 5 to 7-membered fused rings; B represents a 5-7 membered aromatic ring containing from 0 to 4 heteroatoms selected from N, O or S; or a polycyclic aromatic group consisting of two or three 5 to 7-membered fused rings; Ar is phenyl, pyridyl, or substituted phenyl; D represents O, S, NH, or methylene; m and n independently represent an integer from 0 to 4; z is 1, or 2; and t and u independently represent an integer from 0 to 4, and the method comprising the steps of: 1) contacting a compound of formula (XI)

with (R¹⁵)(R¹³)P(O)CH(R⁸)COOR¹⁴ or Ar₃P═CR⁸CO₂R¹⁴ to yield a compound of formula (IX)

wherein Y represents CH₂, S, O, or N—R⁹ except NH; R⁸ independently represent H, CF₃, or C₁₋₆alkyl; R⁹ is independently at each occurrence selected from C₁₋₆alkyl, CF₃, CF₂CH₃, (CH₂)₂₋₄OH, (CH₂)₁₋₄OC₁₋₆alkyl, (CH₂)₁₋₄NH(C₁₋₆alkyl), (CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₄, (1-piperidyl)(CH₂)₁₄, (4-morpholinyl)(CH₂)₁₋₄, C(O)C₁₋₆alkyl, C(O)(CH₂)₁₋₄OH, C(O)(CH₂)₁₋₄OC₁₋₆alkyl, C(O)(CH₂)₁₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₁₋₆C(O), (1-piperidyl)(CH₂)₁₋₆C(O), (4-morpholinyl)(CH₂)₁₋₄C(O), C(O)OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄OC₁₋₆alkyl, C(O)O(CH₂)₂₋₄N(C₁₋₆alkyl)₂, (1-pyrrolinyl)(CH₂)₂₋₄OC(O), (1-piperidyl)(CH₂)₂₋₄OC(O), (4-morpholinyl)(CH₂)₂₋₄OC(O), (CH₂)₁₋₄C(O)OC₁₋₆alkyl, or Ar(CH₂)₁₋₄; R¹³ and R¹⁵ are independently C₁₋₄alkyl, OC₁₋₄alkyl, phenyl, substituted phenyl, phenoxy, or substituted phenoxy; R¹⁴ represents C₁₋₅alkyl; Ar is phenyl or substituted phenyl; and m and n independently represent an integer from 0 to 4; 2) contacting a compound of formula (X)

an acyl chloride, or a mixed anhydride thereof with the compound of formula (IX) as defined in step 1 in the presence of a condensing agent to yield the compound of formula (I); wherein X, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹², A B, D, Ar, m, n, z, t, and u are as in claim 1; Y represents N—R⁹; and R⁹ is not H; 3) transforming the compound of formula (I), wherein X, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹², A, B, D, Ar, m, n, z, t, and u are as in claim 1; Y represents N—R⁹; and R⁹ represents (CH₃)₃OC(O), obtained in step 2) in acidic conditions into the compound of formula (XII)

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹², A, B, D, X, Ar, m, n, z, t, and u are as defined in claims 1; and 4) contacting the compound of formula (XII) as defined in step 3) with R⁹-LG to obtain the compound of formula (I), wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², A B, D, X, Y, Ar, m, n, z, t, and u are as defined in claim 1, and LG represents Cl, Br, I, OMs, or OTs. 